,ticker,content
0,BSX,boston scientific corporation bsx free report be schedule report second quarter result open bell jul last report quarter company earning share beat zack consensus estimate moreover company deliver positive earning surprise trail quarters average beat be let see thing be shape prior announcement key prior quarter be upbeat solid contribution boston scientific cardiovascular business comprise interventional cardiology ic peripheral intervention pi last report quarter company generate total revenue highest revenue generate segment be optimistic ic business help company maintain impressive global growth courtesy innovative portfolio robust commercial team division perform well last report quarter lotus recall europe worldwide ic growth come back strength structural heart complex pci intervention portfolio however upside be partially offset weak performance drug eluting stent boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotewithin structural heart be look forward boston scientific watchman acurate iris product line be expect contribute top line yet be report quarter company expect revenue watchman acurate tavr franchise total approximately watchman program depict impressive performance first quarter product have be used more implant worldwide moreover company expect continue growth platform back increase utilization geographical expansion additionally recent launch ic business wolverine cut balloon company next generation rotational atherectomy platform rotapro be expect contribute significantly top line upcoming quarterly result zack consensus estimate ic revenue be peg indicate increase year year basis company be expect keep gain strength business last report quarter pi business perform impressively back higher sale drug eluting stent ranger balloon europe geographically company witness strength asia well boston scientific atherectomy jetstream platform also perform well first quarter trend be expect continue be report quarter accordingly zack consensus estimate second quarter pi revenue be peg reflect rise year year overall zack consensus estimate total revenue indicate increase prior year quarter tally also earning estimate cent reflect rise year year basis other factor playamong other segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project surpass market level drive investment strategy key international geography be impressed boston scientific recent acquisition have add several product many be development immense potential nxthera nvision buyout urology pelvic health emcision buyout endoscopy deserve mention company be gradually strengthen presence emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently look forward improve performance ahead china follow recent approval synergy region boston scientific be gain traction india well be currently target emerge market additional emphasis company be also optimistic core cardiology segment be gradually stabilize growth bric nation trend be expect continue yet be report quarter result however immaterial be report quarter ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect top line number upcoming quarters company also provide second quarter financial outlook adjust ep be expect range cent revenue here quantitative model predictsper proven zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter boston scientific have zack rank increase predictive power esp have earning esp make surprise prediction easier combination suggest company be likely beat earning quarter other stock worth lookhere be few other medical stock worth consider right combination element beat estimate resm rmd free report have earning esp carry zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank henry schein inc hsic free report zack rank company have earning esp medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1,BSX,boston scientific corporation bsx free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have rally compare industry rise also company have surpass breakeven share performance developer manufacturer marketer medical device use interventional medical specialty have market cap company have long term historical earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day only analyst have revise estimate upward movement be noticed opposite direction however earning estimate remain unchanged boston scientific corporation price boston scientific corporation price boston scientific corporation quotelet find recent positive trend be sustainable solid quarterly scientific continue deliver better expect quarterly earning revenue number be upbeat company witness growth business line geography strategic buyout be upbeat boston scientific recent acquisition apama medical deal company aim expand suite arrhythmia solution fall ep sub segment further gain traction ep market boston scientific announce plan acquire securus medical privately hold developer thermal monitoring system continuous measurement esophageal temperature be also look forward company recent agreement acquire cryterion medical privately hold company develop single shot cryoablation platform treatment atrial fibrillation addition cryoballoon platform help boston scientific emerge first entity cryothermal radiofrequency single shot balloon base ablation therapy portfolio geographic expansionboston scientific integral growth strategy be continue pursue developmental opportunity outside unite state expand global presence inclusive emerge market company be gradually fortify footprint emerge market include brazil russia india china first quarter business emerge market register growth company be gain strong ground india well target emerge market additional stimulus boston scientific hope sustain robust overall international performance ride high product launch currently early stage rollout suspension medtech decision house senate suspend medical device tax year have come relief medical device bigwig boston scientific company temporary suspension allow continue investment plan innovative medical product company meanwhile have plan work full repeal medtech tax other stock considerother top rank stock broader medical space include genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate quarter be report stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have estimate long term earning growth rate zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2,BSX,investor focuse medical space have likely hear boston scientific bsx free report be stock perform well comparison rest sector peer quick glance company year date performance comparison rest medical sector help answer question boston scientific be individual stock medical sector collectively company sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank emphasize earning estimate estimate revision find stock improve earning outlook system have long record success stock tend be track beat market next month bsx be currently sporting zack rank buy zack consensus estimate bsx full year earning have moved higher past quarter mean analyst sentiment be stronger stock earning outlook be improve accord latest datum bsx have moved year date basis comparison medical company have return average mean boston scientific be outperform sector whole year break thing more bsx belong medical product industry group include individual company currently sit zack industry rank stock group have gain so far year so bsx be perform better group term year date return go forward investor interested medical stock continue pay close attention bsx look continue solid performance
3,BSX,stryker corporation syk free report second quarter result be schedule release jul market close company acquisition drive strategy be expect boost growth expand product offering segment expect company witness steady growth sale orthopaedic implant major revenue generate component be project drive second quarter earning expect improvement revenue other segment especially medsurg help company drive impressive result notably last report quarter stryker post earning beating zack consensus estimate quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be pin indicate year year increase stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation implant implant contribute net revenue last report quarter last report quarter revenue segment be organically upside be attribute significant year year increase mako robot installation coveted mako platform also record strong performance japan south pacific canada globally stryker install mako robot be unite state zack consensus estimate orthopaedic implant quarter be report be reflect rise year year other factor playmedsurg unit drive growthmedsurg equipment product include surgical equipment surgical navigation system endoscopic communication digital imaging system well patient handle emergency medical equipment last report quarter segment account company net sale revenue segment grow constant currency cc moreover zack consensus estimate medsurg equipment revenue be peg reflect year year growth domestic international revenuesstryker be well balanced high domestic international revenue last report quarter domestic revenue account significant net sale meanwhile international sale account total revenue zack consensus estimate stryker domestic sale be pin year year same international revenue stand year year complete buyout entellus medical entellus be integrate stryker core neurotechnology spine segment enable physician conveniently perform broad range ent procedure however acquisition be expect be dilutive initially stryker adjust earning share approximately cent be likely affect top line quarter be report read more stryker close entellus buyout bolster neurotechnology line stryker be lately news make offer take massachusett base boston scientific corporation bsx free report however further term deal have be reveal stryker stryker also sign agreement acquire safeair ag swiss medical device company recently model predictsour quantitative model do not predict earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated earning esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
4,BSX,boston scientific corporation bsx free report recently announce acquisition cryterion medical inc privately hold developer single shot cryoablation platform treatment atrial fibrillation acquisition boston scientific become only company boast comprehensive portfolio cover cryothermal radiofrequency single shot balloon base ablation therapy cryterion medical plan submit clinical evidence ongoing study cryoablation system get ce mark early further company plan submit investigational device exemption application fda seek regulatory approval unite state financial term dealboston scientific have exist investment cryterion medical be go make net upfront payment approximately cash remain stake however transaction be not expect be accretive company adjust earning share glimpse ep businessboston scientific ep business develop less invasive medical technology diagnose treat disorder heart rate well rhythm first quarter revenue division improve year year organically upside be drive higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently launch platform unite state well japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system additionally focus add tool expand reach utility rhythmia hdx different procedure moreover expand ep business boston scientific recently announce acquisition securus medical group inc privately hold developer thermal monitoring system continuous measurement esophageal temperature market potentialboston scientific strategy boost ep business seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect reach value cagr company global ep market be expect worth further grow double digit single shot ablation therapy be estimate be most rapidly grow sub segment ep market thus addition single shot cryoablation platform help boston scientific cash abundant opportunity global cardiac monitoring cardiac rhythm management market share price scientific have be gain investor confidence consistently positive result past month share company have outperformed broader industry stock have rally versus industry increase zack rank other key picksboston scientific currently carry zack rank buy other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
5,BSX,baxter international bax free report be currently top perform stock medtech space company raise guidance global expansion be major tailwind share upin past year baxter share have rally compare industry growth zack rank buy stock currently have growth score reflect possibility outperformance long haul research show stock growth score combine zack rank strong buy be better pick most last day zack consensus estimate baxter current quarter earning share rise cent baxter international inc price consensus baxter international inc price consensus baxter international inc quotewhat make attractive pick raise guidancebaxter have raise guidance company expect sale growth cc expect adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range acquisition recently complete acquisition hemostat sealant product mallinckrodt plc widen surgical portfolio company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter also recently collaborate international society nephrology isn spread awareness chronic kidney disease international launchesbaxter aim accelerate growth offer service overseas company advanced surgery team recently begin rollout tisseel prima europe japan baxter renal team have initiate launch kaguya peritoneal dialysis technology want more industry other top rank stock medical product space be stryker corp syk free report bio rad laboratory bio free report boston scientific corp bsx free report stryker long term expect earning growth be stock carry zack rank see complete list today zack rank stock here bio rad long term project earning growth be stock carry zack rank boston scientific have expect long term earning growth stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
6,BSX,re look profitable portfolio stock offer best value growth investing try growth reasonable price garp strategy help investor gain exposure stock be undervalue have impressive growth prospect however not confuse garp investing blend strategy blend strategy promote investment value growth stock garp investing require value growth feature single stock garp metric mix growth value metricsthe garp approach prefer stock be price market reasonable target determine fundamental analysis stock also have solid prospect term cash flow revenue earning share ep so growth metricsstrong earning growth history impressive earning prospect be main concept garp investor borrow growth investing strategy however instead super normal growth rate pursue stock more stable reasonable growth rate be also tactic garp investor hence growth rate be consider ideal garp strategy growth metric be consider growth garp investor be return equity roe garp investor look strong higher roe compare industry average identify superior stock moreover stock positive cash flow find precedence garp plan value metricsgarp investing give priority popular value metric price earning ratio investing style pick stock higher ratio compare value investor avoid company extremely high ratio moreover price book value ratio be also consider used garp principle have run screen identify stock offer solid return term screening parametersalong criterium discuss section have consider favorable zack rank strong buy buy last year ep project year ep growth rate strong ep growth history prospect ensure improve business roe past month greater industry average higher roe compare industry average indicate superior stock ratio less industry average ratio less industry indicate stock be undervalue here be stock make screen anthem inc antm free report be health care company company provide medical product subsidiary zack rank stock deliver average quarter earning surprise see complete list today zack rank stock here vmware inc vmw free report provide virtualization solution desktop datum center company deliver average quarter positive earning surprise have zack rank merit medical system inc mmsi free report set build world most customer focuse healthcare company understand customer need innovate deliver diverse range product improve life person family community world zack rank stock deliver average quarter earning surprise boston scientific corporation bsx free report transform life innovative medical solution improve health patient world zack rank stock deliver average quarter earning surprise grand canyon education inc lope free report be regionally accredit provider online postsecondary education service focuse offer graduate undergraduate degree program core discipline education business healthcare zack rank stock deliver average quarter earning surprise petm express inc pet free report be lead nationwide pet pharmacy zack rank stock come average quarter earning surprise aptiv plc aptv free report be technology company serve automotive sector company design manufacture vehicle component provide electrical electronic active safety technology solution global automotive commercial vehicle market zack rank stock deliver positive earning surprise last quarter get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
7,BSX,investor interested stock medical product sector have probably already hear lonza group ag lzagy free report boston scientific bsx free report company be best option look undervalue stock let take closer look have find best way great value opportunity be pair strong zack rank great grade value category style score system zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait right now lonza group ag boston scientific be sporting zack rank buy zack rank favor stock have recently see positive revision earning estimate so investor rest assured company have improve earning outlook be just piece puzzle value investor value investor also try analyze wide range traditional figure metric help determine company be undervalue current share price level value category grade stock base number key metric include try true ratio ratio earning yield cash flow share well variety other fundamental value investor frequently use lzagy currently have forward ratio bsx have forward also note lzagy have peg ratio metric be used similarly famous ratio peg ratio also take account stock expect earning growth rate bsx currently have peg ratio notable valuation metric lzagy be ratio investor use ratio look stock market value versus book value be defined total asset total liability comparison bsx have be just few metric contribute lzagy value grade bsx value grade lzagy bsx be impressive stock solid earning outlook base valuation figure feel lzagy be superior value option right now
8,BSX,walgreen boot alliance inc wba free report be slate release third quarter fiscal result market open jun last quarter company deliver positive earning surprise walgreen boot have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement key catalystsover recent past walgreen boot retail pharmacy usa division have witness comparable prescription growth benefit strength retail prescription market notably revenue division account total second quarter fiscal revenue several plan development early benefit new pharmacy contract well increase volume owing previously announce pharmacy partnership have be drive growth space same time company have be gain strategic partnership fedex respect exist store last report quarter walgreen boot witness strength pharmacy sale account increase prescription volume company have already start gain recently acquire rite aid store walgreen boot alliance inc price ep surprise walgreen boot alliance inc price ep surprise walgreen boot alliance inc quotemoreover retail pharmacy market have be see rise expenditure prescription drug grow demand specialty drug furthermore company effort boost digital capability have start pay regard company retail resale script be initiate digital channel walgreen mobile app record download launch zack consensus estimate total revenue retail pharmacy usa division reflect rise year meanwhile tough market condition particularly retail have be lead sluggishness retail pharmacy international division however company have be take action enter tie up control cost boost segment zack consensus estimate revenue retail pharmacy international division highlight improvement prior year quarter strong growth certain emerge market be expect continue drive company pharmaceutical wholesale division zack consensus estimate division revenue show rise prior year quarter zack consensus estimate total revenue reflect rise year year basis flip side walgreen boot gross margin figure have be decline recent past however company be work gain efficiency provide high quality cost effective pharmacy service order reduce pharmacy cost overall walgreen boot fiscal earning outlook look quite promising company expect register ep range zack consensus estimate earning share remain guidance range here be quantitative model predict walgreen boot have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp walgreen boot be uncover best stock buy sell re report earning esp filter zack rank walgreen boot carry zack rank zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter align technology inc algn free report have earning esp zack rank buy see complete list today zack rank strong buy stock here boston scientific corporation bsx free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
9,BSX,several tailwind gradually flow opportunity be grow enormously medical device space sector be currently enjoy investment world attention investor be putt effort pick subindustry be beam prospect name pop first be cardiovascular device market world health organization cardiovascular disease be disorder heart blood vessel include coronary heart disease cerebrovascular disease rheumatic heart disease other condition go latest heart disease stroke statistic report american heart association adult be live form cardiovascular disease effect stroke further cardiovascular disease have be deem be major cause death person unite state notably be gradually take shape deadly epidemic globally scenario be quite intriguing report cardiovascular disease be major cause global death take life person notably projection related disease hint continuation present trend regard number death globally due cardiovascular disease be expect increase more moreover total direct expenditure related cardiovascular disease be expect rise go say rise incidence cardiovascular disease globally have open opportunity cardiovascular device maker market be expect witness cagr reach report visiongain accordingly investor be keen effectively put money longer term gain cardiovascular device market undoubtedly hold immense potential factor drive cardiovascular device marketrising healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand center medicare medicaid service report publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue cardiovascular device market be largely dependent age population census bureau report person age more be likely total almost double estimate population datum also show median age be increase most area country global scenario be pretty similar strengthen emerge market have be contribute largely rise demand cardiovascular device article lead market intelligence firm life science intelligence demand cardiovascular device have be grow solid double digit rate many emerge country include bric nation brazil russia india china turkey late ai bring new eraaccord research firm techemergence ai be be broadly used follow category better management cardiovascular disease artificial intelligence be be apply automate atrial fibrillation process fall ecg monitoring category be also be used company accurately predict risk cardiovascular disease related impact finally company be also involved actively used ai platform improve accuracy patient scan detect cardiovascular disease be certain development deserve mention here lead digital health company analytic life be actively involved design machine learn algorithm detect coronary artery disease invasively radiation accelerate heart cardiotrack india base start recently introduce technology platform used hand hold device cloud storage artificial intelligence capture analyze signal specific heart condition stock watch forwe have select company believe tap promising prospect cardiovascular device market boston scientific corporation bsx free report zack rank buy company have cardiovascular cardiac rhythm management crm reportable segment cardiovascular include interventional cardiology peripheral intervention business company be lead player interventional cardiology market coronary stent product offering see complete list today zack rank strong buy stock here company also market balloon catheter rotational atherectomy system guide wire guide catheter embolic protection device diagnostic catheter well intravascular ultrasound imaging system crm segment company deal implantable device monitor heart deliver electricity treat cardiac abnormality boston scientific project earning growth rate current year be stock deliver positive earning surprise trail quarters average beat past month boston scientific outperformed industry stock have improve compare industry gain period medtronic plc mdt free report zack rank hold company have cardiac vascular group cvg reportable segment cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv crhf division develop manufacture commercialize product diagnosis treatment management heart rhythm disorder heart failure apv division offer comprehensive portfolio product therapy treat aortic disease such aneurysm dissection transection well peripheral vascular disease critical limb ischemia further csh division offer therapy treat coronary artery disease heart valve disorder medtronic have expect earning growth rate current year stock have deliver positive earning surprise trail quarters average beat past month medtronic outperformed industry stock have improve compare industry gain period abbott laboratory free report zack rank company have cardiovascular neuromodulation business broader medical device segment company offer wide range rhythm management heart failure vascular structural heart device treatment cardiovascular disease well neuromodulation device management chronic pain movement disorder product be manufacture market distribute globally heart failure related product include heartmate left ventricular device family vascular product include xience family drug eluting coronary stent system develop multus link vision platform rhythm management product include assurity mri endurity mri pacemaker system be prominent product offer company abbott have expect earning growth rate current year stock have deliver positive earning surprise trail quarters average beat past month abbott outperformed industry stock have improve compare industry gain period conclusiona say strike iron be hot be opportune time cash bountiful opportunity rapidly grow cardiovascular device market make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
10,BSX,uncertainty grip equity market news trump administration be mull impose tariff import car cite obscure ruling protect domestic auto manufacturer purported move be likely backfire adversely impact operation several auto manufacturing firm lead job loss decline production again again trade war unite state china still remain potential threat domestic trade concern appear far be likely continue weigh equity market investor employ see approach classic example back fill market benefit cash cow stock garner higher return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe roe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be multiply profit investing new equity capital portray management efficiency reward shareholder attractive risk adjust return screening parametersin order shortlist stock be cash rich high roe have add cash flow greater roe more industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen general motor company gm free report founder detroit mi base general motor be lead global automotive firm company be engage design build selling car truck crossover automobile part worldwide company have trail quarter average positive earning surprise long term earning growth expectation general motor currently carry zack rank boston scientific corporation bsx free report headquarter natick founder boston scientific manufacture medical device product used various interventional medical specialty worldwide company currently have zack rank have trail quarter average positive earning surprise long term earning growth expectation rowe price group inc trow free report headquarter baltimore rowe price group be global investment management organization provide broad array mutual fund sub advisory service separate account management individual institutional investor retirement plan financial intermediary zack rank stock have long term earning growth expectation trail quarter average positive earning surprise amc network inc amcx free report headquarter new york amc network be engage produce programming movie content own operate various cable television company have trail quarter average positive earning surprise long term earning growth expectation amc network currently carry zack rank see complete list today zack rank stock here celanese corporation ce free report texas base celanese be global hybrid chemical company diverse product rank first second respective market base market share zack rank stock have trail quarter average positive earning surprise long term earning growth projection get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
11,BSX,investor focuse medical space have likely hear boston scientific bsx free report be stock perform well comparison rest sector peer simple way answer question be take look year date performance bsx rest medical group stock boston scientific be company medical group medical group currently sit zack sector rank zack sector rank gauge strength individual sector group measure average zack rank individual stock group zack rank be successful stock pick model emphasize earning estimate estimate revision system highlight number different stock be poise outperform broader market next month bsx be currently sporting zack rank buy zack consensus estimate bsx full year earning have moved higher past quarter show analyst sentiment have improve company earning outlook be stronger base most recent datum bsx have return so far year comparison medical company have return average mean boston scientific be outperform sector whole year breaking thing more bsx be member medical product industry include individual company currently sit zack industry rank stock group have gain so far year so bsx be perform better group term year date return bsx likely be look continue solid performance so investor interested medical stock continue pay close attention company
12,BSX,medical device industry have be benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model further consider favorable demographic change market dynamic artificial intelligence ai big datum application increase business investment sector have be go strong broadly speaking latest tax cut job act slash corporate tax rate earlier have also buoy optimism investor additionally senate decision defer implementation industry wide excise tax know medical device couple year have instilled confidence investor tax be effective jan bill also delay cadillac tax tax employer insurance emergo medical device industry be project reach market value boston scientific corporation bsx free report baxter international inc bax free report be close contender space notably stock carry zack rank buy raise investor optimism here make detailed analysis company fundamental determine stock be currently position better medical product space market cap boston scientific be lead manufacturer medical device product used various interventional medical specialty worldwide other hand base deerfield il baxter be lead global medical technology company company have market cap price performancein past year boston scientific share have gain compare industry increase stock have also surpass index increase share baxter have rise period earning zack consensus estimate boston scientific current year earning be peg share reflect year year project growth same baxter be peg indicate year year rise moreover last year datum boston scientific earning share have witness cagr baxter earning be project negative cagr totale hence boston scientific win round sale zack consensus estimate boston scientific current year revenue be peg show year year growth same baxter be pin reflect year year growth boston scientific revenue witness cagr reach baxter revenue depict negative cagr here too boston scientific win baxter factor drive stocksboston scientificover recently report quarters boston scientific demonstrated growth business line geography view also paint bright picture company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum boston scientific recently announce several acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be positive buyout recothorm preveleak be noteworthy well recently company get fda approval spectrum iq infusion system baxter surgical portfolio be highly diversify product available more country include exclusive product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other conclusionour comparative analysis indicate boston scientific be position better baxter consider price performance well earning sale growth other key picksother top rank stock broader medical sector be illumina inc ilmn free report idexx laboratory inc idxx free report illumina sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here illumina expect long term earning growth idexx have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
13,BSX,again again trade war unite state china take new turn president trump impose fresh salvo tariff worth chinese import last week follow immediate retaliation china promise match scale trade restriction vast array good flurry event cause mild slide most benchmark index tension brew investor community overall economic sentiment appear bullish improve wage promising labor market condition prompt fed increase interest rate domestic trade concern appear far be likely weigh equity market investor employ see approach classic example back fill market benefit cash cow stock garner higher return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe key metricroe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be multiply profit investing new equity capital portray management efficiency reward shareholder attractive risk adjust return parameter used screeningin order shortlist stock be cash rich high roe have add cash flow greater roe more industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen general motor company gm free report founder detroit mi base general motor be lead global automotive firm company be engage design build selling car truck crossover automobile part worldwide company have trail quarter average positive earning surprise long term earning growth expectation general motor currently carry zack rank boston scientific corporation bsx free report headquarter natick founder boston scientific manufacture medical device product used various interventional medical specialty worldwide company currently have zack rank have trail quarter average positive earning surprise long term earning growth expectation nrg energy inc nrg free report nrg energy be engage production sale delivery energy energy product service residential industrial commercial consumer major competitive power market unite state have financial commercial headquarters princeton nj operational headquarters houston tx zack rank stock have stellar trail quarter average positive earning surprise amc network inc amcx free report headquarter new york amc network be engage produce programming movie content own operate various cable television company have trail quarter average positive earning surprise long term earning growth expectation amc network currently carry zack rank see complete list today zack rank stock here celanese corporation ce free report texas base celanese be global hybrid chemical company diverse product rank first second respective market base market share zack rank stock have trail quarter average positive earning surprise long term earning growth projection get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
14,BSX,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
15,BSX,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
16,BSX,growth reasonable price garp be excellent way investor make quick gain strategy help investor gain exposure stock have impressive prospect be trading discount garp approach lead identification stock be price market reasonable target determine fundamental analysis stock also have solid prospect term cash flow revenue earning share ep so mean portfolio create basis garp strategy be expect have stock offer best value growth investing growth metricsstrong earning growth solid prospect be main concept garp investor borrow growth investing strategy however instead super normal growth rate pick stock more stable reasonable growth rate be prefer tactic garp investor hence growth rate be consider ideal strategy growth metric be consider growth garp investor be return equity roe garp investor look strong higher roe compare industry average identify superior stock moreover stock positive cash flow find precedence garp plan value metricsgarp investing give priority popular value metric price earning ratio investing style pick stock higher ratio compare value investor avoid company extremely high ratio moreover price book value ratio be value metric be consider used garp principle have run screen identify stock be likely offer solid return term screening parametersalong criterium discuss section have consider favorable zack rank strong buy buy last year ep project year ep growth rate strong ep growth history prospect ensure improve business roe past month greater industry average higher roe compare industry average indicate superior stock ratio less industry average ratio less industry indicate stock be undervalue here be stock make screen vmware inc vmw free report provide virtualization solution desktop datum center zack rank stock deliver average quarter earning surprise see complete list today zack rank stock here boston scientific corporation bsx free report transform life innovative medical solution improve health patient world zack rank stock deliver average quarter earning surprise factset research system inc fds free report create flexible open datum software solution ten thousand investment professional world provide instant access financial datum analytic investor use make crucial investment decision zack rank stock deliver average quarter earning surprise grand canyon education inc lope free report be regionally accredit provider online postsecondary education service focuse offer graduate undergraduate degree program core discipline education business healthcare zack rank stock deliver average quarter earning surprise anthem inc antm free report be health care company provide medical product subsidiary company deliver average quarter positive earning surprise carry zack rank petm express inc pet free report be lead nationwide pet pharmacy zack rank stock come average quarter earning surprise aptiv plc aptv free report be technology company serve automotive sector company design manufacture vehicle component provide electrical electronic active safety technology solution global automotive commercial vehicle market zack rank stock deliver positive earning surprise last quarter get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
17,BSX,medical instrument industry broader medical universe have be gain innovation higher consolidation focus emerge market tax abolition industry increase month time higher index rise fundamentally industry have benefit massive change consumer behavior well be evident rise minimally invasive surgery higher demand liquid biopsy test well use quick improve patient care shift payment system value base model be interesting analyze best medical instrument stock be likely yield solid return day come first let glance latest headline space latest medical instrument headline glance stryker takeover plan boston medical instrument fraternity have be ride current merger acquisition trend recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more however possibility deal be uncertain thre be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific company acquire boston scientific neurovascular unit indicate probability second collaboration read more stryker likely acquire boston scientific stryker have zack rank buy deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience reduce pricing pressure competition further company strong acquisition policy gain rapidly expand customer base moderate leverage enhance cash flow glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention abiom reserve slot lead medical instrument player abiom inc abmd free report replace wyndham worldwide corp enter global industry classification standard gic health care supply sub industry index research report globe mail abiom be follow trend medical device technology company reserve top slot index remind investor align technology inc algn free report top index abiom currently have market capitalization further company financial viability adequate liquidity reasonable price sector representation have lend competitive edge medical instrument industry read more abiom replace wyndham benchmark tax abolition boost da bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief tax take toll entire medical device industry enactment advanced medical technology association lobbying group tax have negative impact medical innovation result loss defer creation job now deferral encourage activity space repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have invoked massive investment sector top medical instrument existence number player medical instrument industry choose right stock potential yield return be daunting task proprietary zack methodology make fairly simple have take help zack stock screener select favorable stock have select stock have favorable growth style score carry zack rank strong buy research show stock style score combine zack rank offer best investment opportunity see complete list today zack rank stock here varian medical system inc var free report outperformed industry month time stock have return have zack rank zack consensus estimate full year earning be currently peg year year june varian medical system demonstrated comprehensive portfolio advanced brachytherapy solution american brachytherapy society annual meeting development be likely boost varian oncology system segment apart various volumetric modulate arc therapy vmat stereotactic radiosurgery stereotactic radiotherapy brachytherapy unit be significant contributor oncology system company have be gain consistently coveted halcyon platform cost effective radiotherapy cancer treatment system notably company also launch halcyon kilovoltage imaging solid revenue oncology grow adoption particle therapy strong overseas presence particularly emerge country be positive varian have also be go global acquisition agreement recent buyout include sirtex australia coop taiwan partnership ministry health brazil solid guidance fiscal instill confidence intuitive surgical inc isrg free report outperformed industry month stock have rise almost sport zack rank zack consensus estimate full year earning be currently peg year year grow adoption company da vinci system increase procedure volume continuous innovation solid recur revenue base be key catalyst intuitive surgical da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery da vinci system be power robotic technology allow surgeon hand movement be translate smaller precise movement tiny instrument patient body da vinci have bolster company foothold market cardiac surgery colorectal surgery general surgery gynecologic surgery head neck surgery thoracic surgery urologic surgery da vinci system have make available minimally invasive surgery more patient worldwide recently system have cure patient diagnosed inguinal hernia integer holding corporation itgr free report outperformed industry last month stock have return industry decline zack consensus estimate full year earning be currently peg year year company witness impressive start high organic year year growth earning revenue cardio vascular arm deserve special mention here other segment have also be deliver solid performance strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove profitable quarters ahead company have multus year plan long term development impressive guidance decline operate expense clear debt be other major positive hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
18,BSX,share boston scientific corporation bsx free report gain close jun follow speculation company rival stryker corporation syk free report consider bid acquire former news be wall street journal report trading stock be temporarily pause monday session nyse yesterday close boston scientific market cap be compare stryker follow reuter report state be still unclear boston scientific be open potential buyout proposal stryker prospective acquirer too decline comment report meanwhile benzinga report write bid have surpass share accord stifel nicolaus well fargo predict share be value base becton dickinson cr bard deal accord bloomberg previous bsx stryker be not first time stryker boston scientific have come strategic collaboration back orthopaedic device giant buy boston scientific neurovascular unit time rationale divestment decision boston scientific come part company aggressive restructure initiative more specifically neurovascular division company core business be struggle depress sale rationale latest rumore boston scientific position prospect possible sell rumor be still unknown analyst believe reason company contemplation probable sell lie interest gain further competitive edge medical device space be important note post colossal merger medtronic mdt free report covidien abbott free report st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space merger get materialize finally consider boston scientific stryker present market cap then consolidated entity have combine market cap more accord well fargo security be position only medtronic johnson johnson term total device revenue react widely speculate buyout bid retire twin city med tech stock analyst thom gunderson say make perfect sense go big go home be rule day analyst seem optimistic allege deal believe finally work boston scientific score vantage point fast grow competitive heart valve replacement market be currently trail edward lifescience ew free report medtronic also merger be expect reduce cost combine company time healthcare industry be already battle severe pricing pressure share price comparisonover past year share boston scientific have rally ahead stryker increase broader sector remain much rise boston scientific stryker currently carry zack rank buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
19,BSX,envision healthcare corp evhc free report share increase private equity firm kkr co have reach deal buy company cashboston scientific corp bsx free report surge follow report wall street journal rival stryker corp syk free report have offer bid buy companysempra energy sre free report share jump follow news activist investor elliot management bluescape resource have suggest value creation strategy companyshare adient plc adnt free report plunge project yearly adjust ebitda fiscal lower previous estimate
20,BSX,boston scientific corporation bsx free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session continue recent uptrend company stock be now past month time frame upside be drive report potential buyout medical instrument maker company have see estimate revision increase decrease past few week zack consensus estimate current quarter remain unchanged recent price action be encourage so make sure keep close watch firm future boston scientific currently have zack rank buy earning esp be positive boston scientific corporation price boston scientific corporation price boston scientific corporation quoteanother stock worth consider medical product industry be terumo corp trumy free report carry zack rank strong buy see complete list today zack rank stock here be bsx go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
21,BSX,recent report reuter stryker corporation syk free report be likely take boston scientific corporation bsx free report create market value more deal materialize combine entity have medtech broadest spectrum product offering include cardiology orthopaedic surgical supply neuroscience yesterday share stryker have drop close boston scientific share have increase close likely be deal materialize chance deal be uncertain be confirmatory statement press release company representative fact investor never forget stryker highly rumore acquisition plan nephew never materialize brighter side be not first time stryker have be tie boston scientific stryker acquire boston scientific neurovascular unit indicate probability second collaboration now however reach particular conclusion moment be bit too early analyst wall street journal claim agreement be largest year be shape be busiest ever merger acquisition deal mature well fargo security analyst lawrence expect outpace medtronic mdt free report johnson johnson jnj free report total device revenue morningstar analyst debbie wang focuse need increase consolidation healthcare provide comprehensive product portfolio customer stryker suppose deal boston scientific seem prudent regard stryker benefit deal happen stryker gain control boston scientific line heart device such stent defibrillator watchman device prevent blood clot boston scientific achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device further company also leverage boston scientific solid foothold underpenetrated emerge economy company also register double digit growth year year basis emerge market last report quarter deal materialize stryker profit boston scientific strength especially bric nation stryker have zack rank buy share company have outperformed industry year time stock have return almost better industry rise stryker acquisition profile shine brightstryker have be follow acquisition drive strategy boost growth recently company acquire entellus medical inc cash transaction share equity value approximately stryker also acquire vexim vexim specialize development sale vertebral compression fracture solution stryker complete acquisition novadaq net purchase price novadaq be lead developer spy fluorescence imaging technology provide surgeon visualization blood flow perfusion more clinical study array specialty company product portfolio be highly complementary stryker visualization platform let watch stryker manage acquire boston scientific medical world achieve solid benchmark term provide comprehensive suite medtech solution reduce pricing pressure competition further company strong acquisition policy gain rapidly expand large customer base moderate leverage enhance cash flow meanwhile medtech fraternity have be ride ongoing merger acquisition trend make most profitable investment arena glance major acquisition recent past becton dickinson company takeover bard johnson johnson buyout covidien deserve mention datum provide biospectrum asia activity medtech space surge increase value aggregate more more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
22,BSX,issue update research report boston scientific corporation bsx free report company be gain traction emerge market particularly bric zone however product recall issue continue impede growth stock carry zack rank hold past month share boston scientific have outperformed industry several issue stock have gain versus industry decline notably boston scientific post impressive first quarter back growth business line geography view also paint bright picture term boston scientific be leave stone unturned strengthen core business well invest new technology company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum company growth first quarter boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus millipede structural heart inorganic expansion plan bode well stock operational efficiency also gradually improve foreign exchange scenario have start contribute company overall top line performance boston scientific be pull stop pump resource new technology global market accounting higher sale geographical region third quarter additionally be encourage company number approval gain product domestic well overseas market however be concern company recall prime product lotus range heart device fate lotus valve issue throw thro uncertainty more time boston scientific recently company announce delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state follow product voluntary recall february latest update company expect launch lotus edge unite state european market not currently fear indefinite future company fast grow transcatheter aortic valve replacement tavr business interventional cardiology lotus valve line be prime product key picksa few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
23,BSX,equity market seem be brace roller coaster ride president donald trump flip flopped trade policy china renew threat impose tariff worth chinese good retaliate unfair trade practice volte face derail trade negotiation war country reduce unite state negative balance trade china vouch counter move similar trade restriction overall market re-cover sudden steep sell trigger italy political crisis threaten stability eurozone establishment party renew effort form government domestic trade concern appear far investor employ see approach classic example back fill market benefit cash cow stock garner higher return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe roe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be multiply profit investing new equity capital portray management efficiency reward shareholder attractive risk adjust return screening parametersin order shortlist stock be cash rich high roe have add cash flow greater roe more industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen general motor company gm free report founder detroit mi base general motor be lead global automotive firm company be engage design build selling car truck crossover automobile part worldwide company have trail quarter average positive earning surprise long term earning growth expectation general motor currently carry zack rank boston scientific corporation bsx free report headquarter natick founder boston scientific manufacture medical device product used various interventional medical specialty worldwide company currently have zack rank have trail quarter average positive earning surprise long term earning growth expectation amc network inc amcx free report headquarter new york amc network be engage produce programming movie content own operate various cable television company have trail quarter average positive earning surprise long term earning growth expectation amc network currently carry zack rank see complete list today zack rank stock here nrg energy inc nrg free report nrg energy be engage production sale delivery energy energy product service residential industrial commercial consumer major competitive power market unite state have financial commercial headquarters princeton nj operational headquarters houston tx zack rank stock have stellar trail quarter average positive earning surprise celanese corporation ce free report texas base celanese be global hybrid chemical company diverse product rank first second respective market base market share zack rank stock have trail quarter average positive earning surprise long term earning growth projection get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
24,BSX,emerge market investment have take backseat late thank nonstop blow economy linger geopolitical tension gulf debt policy related hazard latin america missile test north korea have lead stock investor reconsider outlay market earlier proclaim offer better growth opportunity unite state go msci emerge market index last year annualize growth rate be just other hand gdp capita growth rate last year unite state be international monetary fund world economic outlook database face such adversity goldman sachs statement bloomberg last week address emerge market stock world best bet have create quite stir investment world accord report follow selloff february other market correction investor be keen put money riskier asset emerge economy time msci index have not show significant improvement then comment sheila patel chief executive officer international gsam have force investor think again take asset market go bloomberg report goldman sachs be particularly bet indian healthcare firm consumer stock argentine debt expect india government boost spending public health prime minister narendra modi political risk be ignore investor pessimism mexico argentina be overdo report say emerge market healthcare scenario way better unite patel particularly talk grow prospect indian healthcare market datum show prospect broader emerge market be equally encourage contrary healthcare scenario unite state be muddle survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll next month state past decade marked biggest increase uninsured rate new healthcare reform bring term scenario remain pretty unclear now meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity emerge market opening medtechper recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany other emerge geographical region latin america even face economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare give huge potential region long back johnson johnson jnj free report have set manufacturing center india china brazil company emerge market medical device segment continue grow time faster develop market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report second quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific bsx free report emerge market business register organic growth fourth quarter reflect significant increase growth business china be once again remarkable year year growth pace emerge market have decline pre financial crisis year however market have historically play crucial role large corporation hedge international trade risk accord bcg report go forward emerge market gdp be project grow faster develop economy market account total consumer spending more investor point view be imprudent immense growth potential emerge economy due occasional rough spot today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
25,BSX,medical device industry have be ride high optimism courtesy senate latest decision postpone industry wide excise tax year know medical device tax notably tax be effective jan bill also delay so call cadillac tax tax employer insurance repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism medical device tax be tax innovation tax job tax health well be million american patient scott whitaker president ceo advanced medical technology association medical device taxe be originally implement part obamacare taxe impose excise tax medtech manufacturer reduce research development prospect consider headwind senate place temporary suspension taxe january december datum provide medical device trade group ken blackwell article publish daily caller partial year repeal medtech tax result rise investment medtech player however taxe be again bring back jan jan fed come new law respite bill tax cut be medtech fraternity happy revamp staturemedtech company now be able reinvest profit tax saving enhance stature launch new product reduce capital depreciation invest early stage med tech company execute clinical trial fuel next generation life change technology patient report association advancement medical instrumentation suggest big shot boston scientific bsx free report expressed concern email statement regard lesser investment innovative project lead medical facility taxe be back tax repeal be likely reinforce domestic production increase hire skilled professional lower nation overdependence offshore production report suggest complete repeal generate more job very soon increase wage report modern healthcare report suggest job be lose nationally year tax be effect taxe be reestablish nation have suffer cumulative loss job let take quick look major medtech company be go make best recent tax repeal upheaval stock ride high trendsthere be hardly evidence medtech company witness strong growth margin expansion tax repeal however market expect recent tax repeal have favorable impact margin upcoming quarters happen follow company be lead one have take help zack stock screener select favorable stock shortlist stock vast universe medical device have picked one carry zack rank strong buy zack rank buy see complete list today zack rank stock here surmodic inc srdx free report stock sport zack rank past year stock have return higher industry return surmodic effort improve research development stature have be key growth driver company whole product solution pipeline sirolimus base knee dcb drug coat balloon program deserve mention surmodic have be make progress used internally develop dcb balloon platformin drug delivery pipeline surmodic receive fda clearance telemark support microcatheter telemark support microcatheter offer superior crossability complex coronary peripheral lesion microcatheter combine surmodic extreme composite shaft technology high performance pristine hydrophilic coating together provide exceptional deliverability kink resistance complex lesion cross first quarter fiscal expense be net sale net sale year quarter edward lifescience corp ew free report stock have zack rank past year stock have return higher industry return december edward lifescience announce strategic framework outlook indicate company long term growth strategy recent progress technology pipeline thv transcatheter heart valf edward lifescience expect maintain leadership global tavr market increase focus expand patient access margin front company anticipate moderate expansion gross margin improve mix partially offset capacity investment more specifically term capacity investment heavy investment be go facility expand capacity unite state outside edward lifescience also expect global tavr opportunity exceed haemonetic corporation hae free report stock sport zack rank past year stock have return higher industry return continue momentum new business generation geographical expansion have help company deliver strong result quarter company strong cash position boost investor confidence expansion gross operate margin buoy optimism raise fiscal adjust earning guidance be also impressive paradoxnot forget brunt tax relief be huge report publish congressional budget office cbo project year suspension cost federal government period federal budget deficit next decade notably federal budget deficit reach first month current fiscal more deficit first quarter fiscal however republican spurn concern belief tax cut drive faster growth national prosperity don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
26,BSX,share yy inc yy free report surge report fourth quarter earning share surpass zack consensus estimate xl group ltd xl free report share gain french insurer axa announce plan buy former billionshare boston scientific corporation bsx free report gain company announce plan acquire emcision undisclosed amountwalmart inc wmt free report share surge retail giant announce be plan launch meal kit more store year
27,BSX,boston scientific bsx free report recently broaden endoscopy portfolio buyout privately hold company emcision limit presence canada financial term deal have be keep wrapped company expect deal prove accretive earning post post acquisition boston scientific endoscopy portfolio include emcision fda approve ce marked habib endohpb probe notably habib endohpb probe be innovative endoscopic bipolar radiofrequency device coagulate tissue gi tract moreover habib endohpb probe aids treatment palliative care patient diagnosed cancer glimpse endoscopy businessboston scientific endoscopy division develop manufacture device treat variety digestive disease include affect oesophagus stomach liver pancreas duodenum colon revenue division rise year year last report quarter upside be drive strength biliary hemostasis endochoice ambulatory surgery center portfolio company also witness organic revenue growth segment last november boston scientific complete integration endochoice endoscopy business acquire endochoice holding focus development pathology service infection control product single use device treat variety condition thus believe latest buyout help boston scientific boost top line contribution endoscopy business market prospectsper market datum forecast report global pancreatic cancer therapeutic market be project reach value cagr period upbeat prospect market be primarily base rise consumption tobacco unhealthy lifestyle practice smoking age population obesity company death annually be attribute cancer globally thus addition habib endohpb probe help boston scientific cash abundant opportunity pancreatic cancer therapeutic market share price movementover past month boston scientific have be outperform industry stock have gain compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
28,BSX,base boston scientific corporation bsx free report be lead global manufacturer medical device be used wide range interventional medical specialty boston scientific technology address wide range health condition business unit be organized global report segment rhythm management cardiovascular medsurg currently boston scientific have zack rank hold change follow fourth quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate remain steady cent share last day boston scientific adjust earning cent share be line zack consensus estimate boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote revenue boston scientific post revenue comfortably beating zack consensus estimate revenue key stat fourth quarter boston scientific cardiovascular segment revenue increase rhythm management segment revenue grow totale also revenue medsurg segment improve major factor boston scientific have post impressive fourth quarter result deliver revenue growth segment moreover company receive fda approval vercise deep brain stimulation dbs system treat symptom parkinson disease also company have win fda approval spectra wavewriter spinal cord stimulator system company have also issue guidance first quarter full year guidance stock price follow earning release share price do not show movement pre market trading session check back later full boston scientific earning report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
29,BSX,transcatheter aortic valve replacement tavr market be project witness cagr report analytic publish reportsnreport have be constantly radar market expert courtesy stir cause forerunner space boston scientific corporation bsx free report last february company voluntarily recall core lotus valve device include lotus depth guard drag share pre market trading session article medical device diagnostic industry sadly again november boston scientific announce further delay re launch lotus edge aortic valve system fail meet commit timeline hurt shareholder sentiment even more article medical device diagnostic industry company have opted piper jaffray healthcare conference new york same day pull stock be follow decline market cap meanwhile rejoice situation be edward lifescience corporation ew free report lead player tavr market encouragingly company share have soar lotus valve device recall last february let take sneak peek brewing market investor be keen effectively put money healthcare space backdropboston scientific have be consistently dominate headline development lotus valve device unpleasant reason last february company have call back lotus valve device due issue related premature release pin connect lotus valve delivery system however be not first time company have face such situation earlier company have retract lotus edge valve system similar ground even have face brunt fda order withdraw unit lotus valve circulation europe due lotus valve get unlock delivery system release company have also be disappointing investor continuously delay filing premarket approval pma fda lotus edge valve system currently company expect lotus edge be back european market not also intend roll same unite state same year nevertheless major market analyst believe such numerous product misstep have always end tarnishing brand image deviate customer clinician interest edward lifescience seize boston scientific hit rough patch issue surround lotus valve device edward lifescience reap maximum benefit solid transcatheter heart valve therapy thvt platform company annual investor conference chairman ceo michael mussallem note come end performance accomplishment year significantly exceed expectation expect be strong year edward lifescience primary factor drive company global growth be prosper transcatheter aortic valve therapy business further assert regard management currently project sale transcatheter heart valve therapy moreover edward lifescience expect global tavr opportunity be more make most company have be fire cylinder lately line edward lifescience have term product pipeline track expect new sapien ultra system feature balloon delivery system next generation sheath technology be launch unite state europe later year also company anticipate begin pivotal trial ce marked centera valve system furthermore edward lifescience expect result partner trial sapien valve be present acc follow fda approval later year note market speculator believe edward lifescience solid global presence particularly high potential region europe japan delay comeback key competitive product boston scientific lotus valve help company further cement hold highly potential tavr space other major player ride gain medtronic plc mdt free report corevalve evolut tavr platform comprise corevalve corevalve evolut corevalve evolut pro system have well maintain company position formidable player tavr space article reuter share medtronic have inched boston scientific announcement withdrawal lotus valve device last february notably company record tavr growth mid unite state low international market last report quarter furthermore post acquisition st jude medical abbott laboratory free report integrate popular ce marked portico tavr former structural heart portfolio be expect gain momentum space boston scientific rebound card winston have rightly say man make mistake only wise man learn mistake unwilling let go bountiful opportunity tavr market boston scientific acquire symetis sa structural heart company focuse minimally invasive tavr device company have start selling acurate neo aortic valve europe be also work design acurate neo aortic valve system equip enhance outer sealing skirtfeature moreover boston scientific be look forward leverage exist lotus infrastructure enhance acurate neo valve system better field support geographic expansion next generation product company plan invest unite state japan trial well acurate replace lotus however several opinion have be make round tavr space late market expert believe company eventually replace lotus valve device symetis portfolio other speculate deal have be clinch cushion jitter stem lotus valve device withdrawal few analyst be also opinion boston scientific expend huge amount symetis buyout deal use contingency plan case lotus valve device issue remain unresolved nonetheless dismiss such speculation boston scientific have be consistently emphasize symetis acquisition move broaden tavr suite not replacement lotus valve device end speculation let watch find not boston scientific lotus valve find right weather bloom again zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
30,BSX,boston scientific corporation bsx free report recently present favorable real world datum true hd study annual congress european heart rhythm association ehra latest move be line company strategy gain traction global ep market be poise reach value datum market market study result observational prospective randomize study true hd study cover patient suitable cardiac mapping ablation treat arrhythmia however patient diagnosed atrial fibrillation be not enrolled study notably true hd study evaluate procedural process acute success safety mapping ablation various clinical arrhythmia company study result display safety efficacy rhythmia mapping system used intellamap orion mapping catheter mapping support treatment different type arrhythmia also include case ablation atrial fibrillation base other technique be failure rhythmia mapping systemis catheter base cardiac mapping navigation solution help diagnose treat different type arrhythmia glimpse ep businessboston scientific ep business develop less invasive medical technology diagnose treat disorder heart rate rhythm revenue division fourth quarter improve year year cer upside be drive higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently launch unite state well japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system additionally focus add tool expand reach utility rhythmia hdx different procedure regard boston scientific expect full fledge directsense technology europe unite state follow successful initial launch europe moreover order expand ep business boston scientific acquire apama medical inc october company also intend integrate rhythmia hdx mapping system apama rf balloon system improve visualization heart ablation process market potentialboston scientific strategy boost ep business seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise age population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market be anticipate witness cagr space market be expect witness highest momentum cagr share price scientific have be gain investor confidence consistently positive result last month share company have outperformed broader industry stock have rally compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
31,BSX,feb issue update research report lead medical device company boston scientific corporation bsx free report stock carry zack rank hold notably house senate decision suspend medical device tax year have come breath fresh air medical device mammoth boston scientific company temporary suspension turn allow continue plan investing innovative medical product meanwhile company be intent work complete repeal medtech tax be also encourage boston scientific major investment santa rosa base millipede move be expect consolidate company position grow field mitral regurgitation mr fall structural heart business millipede be developer iris transcatheter annuloplasty ring system treatment severe mr positive note product claim be highly customizable specific patient anatomy disease state apart gradually improve foreign exchange scenario have start contribute company overall top line performance promising view be also impressive flip side decline worldwide pacemaker sale recent past continue weigh boston scientific crm customer relationship management result fourth quarter company witness high single digit decline pacemaker performance due tough comparison draw stronger revenue reap launch company brady mri linepost april late company have take several measure rebound trend term outlook still look bleak additionally fate lotus valve issue seem limbo more time boston scientific recently company announce further delay earlier report timeline commercial return lotus edge aortic valve system europe unite state follow product voluntary recall last february sync downtrend boston scientific have be trading broader industry past month stock have lose compare broader industry rise period key picksa few better rank stock broader medical space be abiom abmd free report athenahealth athn free report cardinal health cah free report sporting zack rank strong buy see complete list today zack rank stock here abiom have expect long term growth rate stock have soar last month surpass broader industry performance athenahealth have project long term growth rate stock have increase last month industry gain cardinal health have estimate long term growth rate last month stock have gain higher industry growth more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
32,BSX,boston scientific corporation bsx free report post adjust earning share ep cent fourth quarter year quarter figure remain line zack consensus estimate fall company guide range cent adjust ep adjustment take consideration estimate net income tax charge related deem repatriation unremitted earning foreign subsidiary partially offset benefit related re measurement company defer taxe arise lower corporate tax rate adjustment company report loss cent share compare ep cent year period full year adjust ep come increase year number however be line zack consensus estimate full year adjust ep also remain company project band revenue detailrevenue fourth quarter be year year report basis operational basis constant exchange rate cer tally remain line company earlier announce preliminary sale result exceed zack consensus estimate revenue be report basis operational basis count boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoteorganic revenue growth fourth quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically fourth quarter company achieve operational growth unite state organically europe asia middle east africa region emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively fourth quarter second largest contributor boston scientific top line be rhythm management comprise cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm decline defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin fourth quarter expand basis point bps year year rise cost product sell adjust operate margin improve bps report quarter quarter selling general administrative expense go research development expense rise royalty expense decrease quarter guidanceboston scientific have provide guidance company project current year earning range annualize growth report basis increase organic basis cer include contribution approximately bps symetis zack consensus estimate current year revenue be peg guide range adjust ep guidance be issue range zack consensus estimate be guide band company also provide first quarter financial outlook adjust earning be expect band cent share revenue consensus mark ep stand cent revenue takeboston scientific post mixed fourth quarter performance earning line zack consensus estimate revenue ahead mark however balanced growth business line geography be impressive also gradually improve foreign exchange scenario have also start contribute company overall topline performance promising view be more encourage indicative overall bullish trend continue term boston scientific be leave stone unturned strengthen core business invest new technology well global market accounting higher sale geography fourth quarter be also optimistic company gain number product approval domestic overseas market recent development worth mention be fda approval company vercise deep brain stimulation system treat symptom parkinson disease spectra wavewriter spinal cord stimulator system simultaneously provide paresthesia base sub perception therapy company have also invest millipede privately hold company have develop iris transcatheter annuloplasty ring system treat severe mitral regurgitation zack rank key picksboston scientific carry zack rank hold few better rank stock report solid earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent bottom line soar year year revenue report quarter rise year year basis perkinelmer release fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower year figure cent top line improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
33,BSX,boston scientific corporation bsx free report have recently announce major investment santa rosa base millipede inc augment position field mitral regurgitation mr millipede be developer iris transcatheter annuloplasty ring system treatment severe mr term agreement boston scientific have purchase portion millipede company have also keep option acquire remain share millipede point time prior completion first human clinical study meet certain parameter also millipede have option compel boston scientific purchase remain share closure clinical study full buyout millipede need additional payment boston scientific further be paid achievement commercial milestone regard management note mr occur leak mitral valve cause blood regurgitate left ventricle left atrium heart condition gradually lead heart failure heart rhythm problem patient severe mr often complain compromise heart function tolerate open heart surgery repair replacement leak valve management be optimistic large patient population space be unfortunately underserved moment hence area represent lucrative market be tap patient population benefit fully percutaneous transcatheter procedure fix dilate mitral reduce regurgitation undergo surgery encouragingly millipede iris annuloplasty ring claim be highly customizable specific patient anatomy disease state device be supply transcatheter transseptal delivery system follow standard surgical approach mend decrease size dilate mitral positive note global transcatheter mitral valve replacement market be grow stupendously cagr approximately datum provide technavio apart boston scientific other major player field be edward lifescience corporation ew free report medtronic plc mdt free report abbott free report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
34,BSX,boston scientific corporation bsx free report be schedule report fourth quarter result open bell feb last quarter company deliver earning line zack consensus estimate however average trail quarter beat be peg let see thing be shape prior announcement preliminary resultson jan boston scientific announce upbeat fourth quarter preliminary sale performance year year preliminary net sale quarter have be forecast report basis operational basis constant exchange rate cer approximately organic basis report preliminary revenue figure lie zack consensus estimate notably organic revenue growth exclude impact change foreign currency exchange rate well sale recent acquisition endochoice holding symetis sa company have announce preliminary net sale reflect growth report basis increase operational basis rise organic basis compare prior year number company preliminary tally again compare favorably zack consensus estimate key catalystsboston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote be optimistic company gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally more specifically company have late successfully gain business strong sale watchman left atrial appendage closure device portfolio complex pci product watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth regard medicare reimbursement rate drg increase average effective oct watchman implant fall development be expect have significantly boost ic business fourth quarter company earlier state expect end more account implant watchman increase reorder rate previously open account however ahead company earning release fourth quarter believe ic business be grossly impact product recall issue europe notably february company recall prime product lotus range heart device europe due device malfunction company also delay submission marketing application lotus edge device recently company have announce further delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state notably recall product last february boston scientific announce expect time reintroduction lotus edge delivery system europe first quarter company also expect file final pre market approval pma module food drug administration january however latest press release company be likely provide further update status lotus edge valve feb delay have be justified boston scientific cite continuous focus manufacturing regulatory milestone support long term success lotus platform company state be work hard implement necessary modification device pass internal quality standard however extra delay lead further setback company fast grow transcatheter aortic valve replacement business ic soon be report quarter zack consensus estimate fourth quarter ic revenue be peg higher year report number other factor playamong segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project grow market level drive investment strategy key international geography zack consensus estimate fourth quarter endoscopy revenue be peg prior year quarter report count urology woman health consensus mark remain ahead year earlier quarter report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market get highly expose currency fluctuation full year boston scientific predict unfavorable foreign exchange challenge tune basis point cent share earning here quantitative model predict boston scientific do not have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat zack esp boston scientific have earning esp make surprise prediction difficult uncover best stock buy sell re report earning esp filter zack rank boston scientific carry zack rank sell lower predictive power esp stock worth lookhere be few medical stock worth consider right combination element beat earning quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp be zack rank player hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
35,BSX,boston scientific corporation bsx free report successful result whisper randomize controlled trial rct further boost neuromodulation business announcement follow recent fda approval spectra wavewriter spinal cord stimulator system scs neuromodulation arm present north american neuromodulation society la vegas whisper rct be multus center prospective cross randomize controlled study evaluate long term safety effectiveness scs therapy datum demonstrated sub perception paresthesia base scs therapy be utilize combine therapy regimen chronic pain relief deliver superior outcome comparison patient single scs therapeutic option notably scs technology send low electrical pulse varied frequency pulse width amplitude spinal cord interrupt pain signal paresthesia base therapy provide pain relief light tingle sensation sub perception therapy work boston scientific study provide favorable datum person suffering chronic pain year also expose challenge long term usage scs management state patient be able choose scs therapy provide most effective pain relief number subject pain be effectively controlled scs increase result also demonstrated lend patient choice use sub perception paresthesia base therapy provide superior patient outcome affirm scs be clinically valuable treatment option regard be encourage note study result remain well align company latest fda approve scs system spectra wavewriter company claim latest technology effectively enable physician patient combine therapeutic option customize therapy capture real time feedback treat chronic debilitating pain address individual distinctive pain relief need spectra wavewriter system disposal boston scientific certainly vouch fact patient easily combine paresthesia base sub perception therapy target specific area pain also provide real time feedback used system remote control datum provide market market global neuromodulation market be project reach cagr boston sciebntfic earlier note more american suffer chronic pain thereby make prime cause disability adult unite state company commitment invest research expansion treatment option chronic pain identify new opioid solution scs appear be perfectly strategic share price movement boston scientific have be outperform broader industry past day stock have gain compare broader industry growth stock considerboston scientific carry zack rank sell better rank stock broader medical space be bio rad laboratory bio free report centene corporation cnc free report molina healthcare inc moh free report sporting zack rank strong buy see complete list today zack rank stock here bio rad have whopping expect growth rate first quarter stock have jump surpass broader industry year centene have expect long term growth rate stock performance bourse have be solid year time high return molina healthcare have sturdy project growth rate last month stock have surge higher broader industry rally today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
36,BSX,year bring ample reason american cheer standpoint latest tax cut job act be finally sign president dec effective jan be income tax bracket offer reduce tax rate corporate tax rate too have be slash earlier apart new legislation have almost double standard deduction nation be delighted huge tax slash economist be quite apprehensive damage healthcare community be realize long go vox article bill also include tax cut so large trigger board spending cut include billion medicare last time medicare be hit cut patient lose access critical service chemotherapy treatment congressional budget office cbo apprehend doesn find alternative meet fiscal deficit huge tax cut automatic cut worth mandatory spending include medicare cut be trigger not only latest law also repeal individual mandate be essential part obamacare prove health coverage majority american cbo expect person drop plan repeal vox article care elderly be disrupt bring erratic change health care system device tax back serious threat medtechwithin medtech space situation be more grave medical device community be earlier extremely hopeful trump regulatory agenda have promise complete abolition infamous medical device tax be first include health care reform law dread tax impose selling price instead net profit amount stupendous sum wipe almost quarter profit medical technology company article publish la time congress device tax be unpopular not only republican many democrat state such massachusett minnesota have large number medical device company realize house senate temporarily suspend year begin go available datum be quite evident partial year repeal medical device tax have benefit sector overall development datum provide medical device trade group ken blackwell article publish daily caller period be roughly rise research development investment medtech player temporary suspension however have take account expectation government permanently put end tax obviously be not go happen undoubtedly comeback be additional burden medtech fraternity largely discourage activity la time article advame medical imaging technology alliance tax take bite medical device industry next decade medtech stock be affected most tax backper article matt murphy wbur sector be likely be hampered most re imposition levy be ray mri machine surgical instrument pacemaker such tumultuous scenario have handpick medtech bigwig be play majorly controversial sector hefty investment year be hence expose significant level risk associate tax reinstatement boston scientific corporation bsx free report medical device mammoth lead player field heart stent boston scientific unimpressive pacemaker performance core crm have be drag recent past accord usa today article zack rank sell company estimate reinstatement tax cost firm boston scientific state post temporary suspension tax invest saving project include partnership mayo clinic combine manufacturing expertise idea advanced medical device product however reinstatement tax hint continue investment program boston scientific corporation price boston scientific corporation price boston scientific corporation quotestryker corporation syk free report giant orthopedic device maker be face hiccup reintroduction device tax company recently announce preliminary sale number state respect tax reform anticipate modest headwind stock currently carry zack rank hold see complete list today zack rank stock here stryker corporation price stryker corporation price stryker corporation nephew snn free report orthopaedic reconstruction advanced wound management sport medicine maker be go face intense pressure medical device tax resume earlier report fiercemedical device reveal temporary suspension deal nephew shell medical device tax however post suspension tax company have accelerate investment product development manufacturing rescue money reinstatement definitely act hindrance path nephew new age innovation development stock currently carry zack rank nephew snat inc price nephew snat inc price nephew snat inc quotezack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
37,BSX,boston scientific bsx free report stock gain jan close trading follow company announcement upbeat fourth quarter preliminary sale performance notably boston scientific be slate release fourth quarter result feb market open year year preliminary net sale quarter have be forecast report basis operational basis constant exchange rate cer approximately organic basis report preliminary revenue figure lie zack consensus estimate notably organic revenue growth exclude impact change foreign currency exchange rate well sale recent acquisition endochoice holding symetis sa company have announce preliminary net sale reflect growth report basis increase operational basis rise organic basis compare prior year number company preliminary figure again compare favourably zack consensus estimate boston scientific have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular segment fourth quarter preliminary performance sale subsegment interventional cardiology peripheral intervention be year year year year operational basis respectively second largest contributor boston scientific top line have be rhythm management include cardiac rhythm management crm crm reflect year year increase sale operational basis sale have shot year year operational basis other segment endoscopy urology pelvic health neuromodulation medsurg broader group also record operational sale growth respectively share price performancein past month boston scientific have be trading broader industry stock have lose compare broader industry gain period significantly boston scientific unimpressive pacemaker performance core crm continue remain drag also base recent announcement further delay relaunch earlier recall lotus range heart device be expect hamper sale well however promising sale announcement be likely revive growth trend great extent believe improve foreign exchange scenario have already start drive company overall top line be also important note company be leave stone unturned strengthen core business invest more global market zack rank key picksboston scientific carry zack rank sell few better rank stock broader medical space be bio rad laboratory bio free report centene corporation cnc free report exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here bio rad have project long term growth rate stock have rally last month outperform industry rise centene have expect growth rate last day stock have gain higher broader industry increase exelixis have impressive growth rate first quarter stock have soar industry decline year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
38,BSX,asia pacific apac be home more half world population so demand healthcare be also exceptionally high region furthermore need cut edge medtech product service be significantly high world apac be exception fact research report mckinsey show apac be expect outpace european union world second largest medtech market pretty soon unite state almost person region be expect enter age group indicate emerge demand healthcare need also apac account third global disease burden further research report statista show medtech market asia pacific region be estimate reach nearly trump focus datum point huge unmet healthcare need apac market investor find president trump recent day long asia trip stop japan south korea china vietnam philippine be positive sign furthermore recent tweet great country be respect again asia see fruit long successful trip many year come be indicative favorable republican stance apac especially respect business trade here take sneak peek major postulate trump recent asia visit bilateral trade agreementtrump promise augment bilateral trade agreement indo pacific nation instill confidence apac policy however trump specifically mentioned agreement be bound follow principle fair reciprocal trade also voiced free open indo pacific trade emphasize increase focus nation japan australia india prospect china pacific be big enough accommodate china unite state say china president xi jinp trump visit china undoubtedly pose serious competitive threat unite state not just healthcare space also electronic semiconductor retail other area jinp statement clearly hint possibility country coexist peacefully political tension also be indicative strategic merger company nation order enhance trade practice medtech company eye apacconsider trump grow focus apac region seem be poise yield accretive return long term fact stakeholder medical universe have be eyee emerge market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space meanwhile health policy debacle unite state deteriorate economic condition europe conclude growth emerge market china india japan other bolster global foothold medtech company take look lead medtech player be tap also gain bountiful opportunity apac market baxter international bax free report baxter solid presence asia precisely india be worth mention company have research hub japan china just report third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline further baxter strong presence peritoneal dialysis nutrition iv fluid anesthesia gase fortify footprint china zack rank buy stock have have impressive run bourse last year stock have return significantly higher broader industry gain corporation bsx free report important part boston scientific growth strategy be continue pursue development opportunity outside unite state just report third quarter business emerge market register organic growth rate remain company target reach sale business china be also remarkable year year company be currently look forward improve performance china banking recent approval synergy boston scientific be also optimistic core cardiology segment be gradually stabilize growth bric nation cardiology capacity china be expect double end india business be project grow more annually zack rank hold stock have yielded stellar return last year way ahead broader industry same time frame see complete list today zack rank stock here intuitive surgical inc isrg free report intuitive surgical grow interest emerge market specifically apac region bode well last couple year company procedure performance asia show continue strength solid growth china japan korea just report third quarter intuitive surgical system placement include japan india new mexico china zack rank hold company have return last year much higher broader industry same period becton dickinson company bdx free report becton dickinson company bd be focuse geographical expansion overseas market particular emerge nation note company be especially focuse broader emerge market india china be see rapid growth economic healthcare sector believe significant emerge market exposure boost company top line turn lead accelerate ep growth bd revenue grow just report fourth quarter fiscal emerge market revenue grow strong year year quarter constant currency drive strong performance greater asia china revenue see double digit growth lead player medtech space be zack rank hold stock have return last year much higher broader industry growth paradoxhowever trump americafirst pitch asia pacific economic cooperation summit apec be hold vietnam november have be serious threat multilateral trade have be clearly portray trump primary focus be be be betterment unite state zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
39,BSX,boston scientific corporation bsx free report post adjust earning share ep cent third quarter year quarter figure remain line zack consensus estimate fall exactly upper end company adjust ep guidance range cent adjustment company report earning cent share year period revenue detailrevenue third quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoteorganic revenue growth third quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically third quarter company achieve operational growth organically europe asia middle east africa region same emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively third quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm decline defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin contract basis point bps year year rise cost product sell adjust operate margin improve marginal bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit third quarter cash cash equivalent end sequential last quarter end third quarter company have total long term debt marginal decline end second quarter guidanceboston scientific have provide update full year guidance banking solid third quarter show gradually improve foreign exchange scenario company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly narrow earlier range zack consensus estimate be guide range company also provide fourth quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takedespite back back natural disaster boston scientific manage register solid third quarter performance earning line zack consensus estimate revenue ahead mark gradually improve foreign exchange scenario have also start contribute company overall topline performance raise guidance be more impressive indicative overall bullish trend continue rest boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography third quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition apama medical developer single shot apama radiofrequency rf balloon catheter system treatment atrial fibrillation apart company receive fda approval formri labele announce launch resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system combine heartlogic heart failure diagnostic enduralife battery technology smartcrt technology apart company receive ce mark update direction use watchman laac device europe company acurate neo transapical aortic valve system have also gain ce mark company expect begin controlled launch europe fourth quarter zack rank other key pickscurrently boston scientific carry zack rank buy other top rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
40,BSX,president donald trump call summit north korean leader kim jong last thursday be quite shocker abandonement summit plan dealt blow underpenetrated emerge market asia be solid source revenue more base multinational company effect political mayhem cause msci broadest index asia pacific share outside japan south korea kospi japan nikkei plummet major wall street index dow jone industrial average lose ground well consider trend downward movement white house decide conduct meeting unite state announce plan send pre advance team singapore prepare trump kim summit jun medtech appear be very few sector shelter investor political tension shrug current volatility medical product industry have return call fall fact analyst believe medtech sector be able strengthen foothold faster rate meeting go plan be be number base medtech company operate asia post success summit company be able spread network north korea augment overall production research statista medtech market asia pacific region be estimate reach worth buoy encourage projection rather be interesting see medical product company be place political turmoil medtech stock gainmeanwhile medical product company have already be gain organic growth innovation higher consolidation tax abolition well focus emerge market include japan south korea china vietnam india philippine more fact stakeholder medical universe have be eyee market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space take look lead medtech player be gain prospect apac market becton dickinson company bdx free report popularly know bd particularly focus broader emerge market india china brazil turkey economic healthcare sector be grow rapidly particular safety engineer product continue drive growth emerge market believe exposure market boost top line turn accelerate ep growth zack rank hold company share have return year significantly higher index gain baxter international bax free report solid presence asia precisely india be worth mention company have research hub japan china recently baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost zack rank buy stock have outperformed index year time stock have return intuitive surgical inc isrg free report grow interest emerge market specifically apac region bode well past year company procedure performance asia project consistent strength company register solid growth china japan korea zack rank strong buy company share have return year see complete list today zack rank stock here boston scientific corporation bsx free report growth strategy comprise pursuit development opportunity outside unite station strengthen global presence inclusive emerge market backdrop flatten decline sale growth develop market unite state europe boston scientific be fortify foothold emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently project improvement performance china banking recent approval synergy zack rank stock have return year thing remember thing be not so easy appear be american never forget former president george bush refer north korea axis evil sponsored terrorism have solid access nuclear weapon further north korea multiple trial nuclear warhead have dampen country relationship analyst believe unforeseen summit not solve age old problem further guarantee kim jong tremendous anger open hostility not offend trump anymore do last week however trump team be expect reach agreement settle north korean nuclear other issue meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
41,BSX,month have go last earning report boston scientific corporation bsx free report share have add time frame recent positive trend continue lead next earning release be bsx due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsboston scientific post adjust earning share ep cent first quarter year quarter earning also surpass zack consensus estimate cent further adjust ep exceed company guide range cent company report ep cent be line year quarter revenue detailrevenue first quarter be year year report basis operational basis constant exchange rate cer revenue figure exceed zack consensus estimate organic revenue growth first quarter exclude impact change foreign currency exchange rate sale acquisition symetis sa be year year geographically first quarter company achieve operational growth unite state same organically europe middle east africa region asia pacific region same latin america canada emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm neuro medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year organically respectively first quarter second largest contributor boston scientific top line be rhythm neuro business comprise cardiac rhythm management crm neuromodulation crm reflect year year increase organic sale report quarter sale go year year organically neuromodulation sale rise year year organically other segment endoscopy urology pelvic health medsurg broader group record sale organically respectively marginsgross margin first quarter expand basis point bps year year rise cost product sell adjust operate margin improve bps report quarter quarter selling general administrative expense go research development expense rise royalty expense inched quarter guidance raisedboston scientific have provide update guidance company project current year revenue range compare previous annualize growth report basis organic basis cer include contribution approximately bps symetis zack consensus estimate current year revenue be peg guide range adjust ep guidance be estimate range compare previous range zack consensus estimate be peg low end guide band company also provide second quarter financial outlook adjust ep be expect band cent revenue consensus mark ep stand cent same revenue be have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotevgm scoresat time bsx have subpar growth score grade same score momentum front stock be also allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate investor probably be better serve look elsewhere outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably bsx have zack rank buy expect average return stock next few month
42,BSX,veeva system inc veev free report report first quarter fiscal adjust earning cent share bottom line beat zack consensus estimate cent improve year quarter figure total revenue be first quarter year year moreover top line surpass zack consensus estimate veeva system strong growth subscription revenue segment drive metric veeva system outperformed industry year date basis company share have gain compare favorably industry rise current level be also higher index return just stock have zack rank hold segmental detailsfirst quarter subscription service revenue be year year upside be backed stronger expect booking quarter review subscription gross margin be expand roughly basis point bps year year company momentum product line especially veeva vault continue drive growth professional service revenue rise almost quarter review service gross margin be bps prior year quarter veeva system inc price consensus ep surprise veeva system inc price consensus ep surprise veeva system inc quotemargin profit report quarter increase year year gross margin veeva system contract bps report quarter operate income be report quarter year quarter level however operate margin contract bps year quarter figure rise operate expense have keep operate margin pressure quarter regard operate expense increase report quarter research development expense increase sale marketing expense rise general administrative expense increase company provide financial guidance second quarter fiscal total revenue be expect range zack consensus estimate be peg be guidance adjust operate income be expect adjust earning share be expect band cent zack consensus estimate be peg cent be guidance fiscal total revenue be anticipate band previous range zack consensus estimate be peg lie guidance adjust earning be project previous range zack consensus estimate metric be peg lie guidance conclusionveeva system exit first quarter fiscal solid note beating zack consensus estimate count solid performance subscription revenue have be key catalyst further bid replace simple custom make datum warehouse unique industry specific datum model veeva system recently introduce veeva nitro new model commercial datum warehouse life science be encourage veeva system consistent effort product innovation launch grow global demand cloud base vault application also boost opportunity flip side high expense operational side be cause drag company margin partially dampening revenue furthermore intense competition saturating life science market be key concern volatility foreign currency exchange rate be headwind earning medtech major glancea few better rank stock broader medical space report solid earning season be boston scientific corporation bsx free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here varian medical report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis stock have zack rank buy boston scientific post adjust earning share cent first quarter year quarter tally earning also surpass zack consensus estimate cent stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
43,BSX,boston scientific corporation bsx free report have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain compare industry gain also company have outperformed gain developer manufacturer marketer medical device use interventional medical specialty have market cap company have earning growth rate next year solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate rise let find recent positive trend be sustainable solid quarterly scientific exit first quarter solid note better expect earning revenue be upbeat company witness growth business line geography strategic buyout fortify ep businesswe be upbeat boston scientific recent acquisition apama medical deal boston scientific aim expand suite arrhythmia solution fall ep sub segment further gain traction ep market boston scientific announce plan acquire securus medical privately hold developer thermal monitoring system continuous measurement esophageal temperature geographic expansionan important part boston scientific growth strategy be continue pursue development opportunity outside unite state expand global presence inclusive emerge market boston scientific be gradually strengthen presence emerge market include brazil russia india china bric first quarter business emerge market register growth company be gain strong ground india well target emerge market additional emphasis boston scientific hope sustain strong overall international performance product launch be early stage rollout suspension medtech decision house senate suspend medical device tax year have come breather medical device bigwig boston scientific accord company temporary suspension allow continue plan invest innovative medical product company meanwhile have plan work full repeal medtech tax other stock considerother top rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
44,BSX,equity market continue breathe easy china trade concern abate president trump pledge support beleaguered chinese telecom firm zte qualcomm nxp merger review process get roll urgency top administration china apprehension related pullout iran nuclear deal remain subtle threat overall market appear be head sail investor employ see approach classic example back fill market benefit cash cow stock garner higher return however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe key metricroe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be multiply profit investing new equity capital portray management efficiency reward shareholder attractive risk adjust return parameter used screeningin order shortlist stock be cash rich high roe have add cash flow greater roe more industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen general motor company gm free report founder detroit mi base general motor be lead global automotive firm company be engage design build selling car truck crossover automobile part worldwide company have trail quarter average positive earning surprise long term earning growth expectation general motor currently carry zack rank boston scientific corporation bsx free report headquarter natick founder boston scientific manufacture medical device product used various interventional medical specialty worldwide company currently have zack rank have trail quarter average positive earning surprise long term earning growth expectation lam research corporation lrcx free report establish headquarter fremont lam research supply wafer fabrication equipment service semiconductor industry product be used semiconductor manufacturer front end wlp process create memory microprocessor other logic integrate circuit broad range electronic device company have trail quarter average positive earning surprise long term earning growth expectation lam research currently sport zack rank see complete list today zack rank stock here nrg energy inc nrg free report nrg energy be engage production sale delivery energy energy product service residential industrial commercial consumer major competitive power market unite state have financial commercial headquarters princeton nj operational headquarters houston tx zack rank stock have stellar trail quarter average positive earning surprise celanese corporation ce free report texas base celanese be global hybrid chemical company diverse product rank first second respective market base market share zack rank stock have trail quarter average positive earning surprise long term earning growth projection get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
45,BSX,boston scientific corporation bsx free report post adjust earning share ep cent first quarter year quarter earning also surpass zack consensus estimate cent further adjust ep exceed company guide range cent company report ep cent be line year quarter revenue detailrevenue first quarter be year year report basis operational basis constant exchange rate cer revenue figure exceed zack consensus estimate organic revenue growth first quarter exclude impact change foreign currency exchange rate sale acquisition symetis sa be year year geographically first quarter company achieve operational growth unite state same organically europe middle east africa region asia pacific region same latin america canada emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm neuro medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year organically respectively first quarter boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation second largest contributor boston scientific top line be rhythm neuro business comprise cardiac rhythm management crm neuromodulation crm reflect year year increase organic sale report quarter sale go year year organically neuromodulation sale rise year year organically other segment endoscopy urology pelvic health medsurg broader group record sale organically respectively marginsgross margin first quarter expand basis point bps year year rise cost product sell adjust operate margin improve bps report quarter quarter selling general administrative expense go research development expense rise royalty expense inched quarter guidance raisedboston scientific have provide update guidance company project current year revenue range compare previous annualize growth report basis organic basis cer include contribution approximately bps symetis zack consensus estimate current year revenue be peg guide range adjust ep guidance be estimate range compare previous range zack consensus estimate be peg low end guide band company also provide second quarter financial outlook adjust ep be expect band cent revenue consensus mark ep stand cent same revenue be takeboston scientific post impressive first quarter growth business line geography be promising well view be also paint bright picture term boston scientific be leave stone unturned strengthen core business invest new technology well global market have account uptick sale geography first quarter be also optimistic company achieve clinical milestone product ranger drug coat balloon watchman left atrial appendage closure laac device quarter boston scientific announce agreement buy minnesota base nxthera deal value privately hold nxthera be developer marketer rezum system unite state europe zack rank key picksboston scientific have zack rank hold few better rank stock broader medical sector be abaxis inc abax free report bio rad laboratory inc bio free report resm inc rmd free report abaxis bio rad sport zack rank strong buy resm carry zack rank buy see complete list today zack rank stock here abaxis be expect release fourth quarter fiscal result apr zack consensus estimate adjust ep be cent revenue be bio rad be expect report first quarter result zack consensus estimate adjust ep be cent revenue be resm be slate release third quarter fiscal result apr zack consensus estimate adjust ep be cent revenue be investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
46,BSX,base boston scientific corporation bsx free report be lead global manufacturer medical device be used wide range interventional medical specialty boston scientific technology address wide range health condition business unit be organized global report segment rhythm management cardiovascular medsurg currently boston scientific have zack rank buy change follow third quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate remain steady cent share last day boston scientific adjust earning cent share be line zack consensus estimate boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quoterevenue boston scientific post revenue comfortably beating zack consensus estimate revenue key stat third quarter boston scientific cardiovascular segment revenue increase rhythm management segment revenue grow totale also revenue medsurg segment improve major factor boston scientific have post impressive third quarter result deliver revenue growth segment moreover report quarter company have receive fda approval mri labele announce launch resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system company have also acquire acquire apama medical inc company have also receive ce mark acurate neo transapical aortic valve system company have raise full year revenue outlook also raise lower end previously provide adjust ep guidance share share stock price follow earning release share price do not show movement pre market trading session check back later full boston scientific earning report later look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
47,BSX,latest earning preview depict bullish run ongoing report cycle oct member total market cap report number total earning member have go higher revenue however investor be concern medical sector zack sector see lot struggle first month year thank political change ongoing policy restructure related battle ensue lack visibility have roil favorable trend sector maintain trail few quarters third quarter expect earning growth rate stand mere revenue growth projection comparison second quarter earning growth be quite impressive revenue growth store medical product space twist turn continue unfold capitol hill scenario medical product space important part medical device subcategory broader medical sector be get gloomier latest executive order release republican point shrink customer base indicate cut demand expensive medical procedure device lead major supply demand disequilibrium space however major medical device player have be pin hope abolition infamous medical device sale tax elimination be far reality consider tax issue investor interested medical product space eagerly await earning report medtech bigwig week let take look major medical product stock slate release quarterly report oct quantitative model stock solid zack rank strong buy buy hold be combine positive earning esp then chance beating estimate be always high uncover best stock buy sell re report earning esp filter boston scientific corporation bsx free report be upbeat medical device stalwart gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally company gain fair share few cardiovascular segment de drug eluting stent continue build momentum worldwide however ahead earning release quarter ic business be likely be grossly impact company product recall issue europe downbeat ic business tangled product recall issue possibly gain boost company recent acquisition switzerland base symetis sa full recovery take time zack consensus estimate third quarter ic revenue be currently peg lower sequentially last quarter report number boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote notably company earning have outpaced zack consensus estimate average trail quarters further zack consensus estimate third quarter earning cent share have remain unchanged last month however have show rally year report figure zack consensus estimate company revenue be peg yet be report quarter improvement year report number boston scientific have earning esp also carry zack rank recall issue hurt boston scientific earning resm inc rmd free report renown worldwide provider generator mask related accessory treatment sleep disordered breathe sdb be expect gain first quarter fiscal strong performance domestic international front company revenue domestic domain be drive solid growth device well low double digit software sale growth previous quarter internationally company receipt french reimbursement approval telemonitoring buoy optimism zack consensus estimate domestic revenue include contribution reflect increase year quarter also zack consensus estimate international revenue indicate rise year quarter overall fiscal first quarter total revenue be project prior year quarter resm inc price ep surprise resm inc price ep surprise resm inc quote notably company earning have outpaced zack consensus estimate average trail quarters resm carry zack rank sell have earning esp see complete list today zack rank stock here read more resm maintain balanced growth earning align technology inc algn free report be upbeat align technology strategic initiative international expansion ensure invisalign treatment grow base patient also last quarter huge increase international case year year encourage investor figure reflect rise demand quarter be report company reach new benchmark patient have adopt invisalign treatment management also anticipate consistent growth asia pacific region bid flourish region company open new invisalign treatment plan facility china align technology inc price ep surprise align technology inc price ep surprise align technology inc quote notably company earning have outpaced zack consensus estimate average trail quarters align have earning esp carry zack rank stock have see zack consensus estimate third quarter earning cent share be revise penny upward last day have also show improvement significant year tally zack consensus estimate company revenue be peg soon be report quarter compare year report figure reflect gain read more invisalign drive align technology earning cerner corporation cern free report cerner be expect show steady growth system sale major revenue component primarily drive third quarter earning expect improvement revenue other segment also help company generate solid result season zack consensus estimate system sale stand third quarter reflect rally almost year quarter growth acute ambulatory ehr sale population health revenue cycle solution service hold promise cerner cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quote last quarter management cerner announce company expect growth support maintenance service segment remain year fact zack consensus estimate segment revenue stand year year basis sequentially notably company earning have outpaced zack consensus estimate average trail quarters zack consensus estimate third quarter earning cent share have remain unchanged last month however have improve year figure zack consensus estimate company revenue be peg yet be report quarter improvement year number cerner have earning esp also carry zack rank read more higher system sale drive cerner earning stryker corporation syk free report august stryker announce voluntary recall oral care line offer company sage product unit add voluntary recall company have place temporary hold certain cloth base product mar third quarter result expect improvement revenue major revenue segment help company generate solid result season stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quote stryker deliver positive earning surprise past quarters average beat be zack consensus estimate third quarter revenue stand year year basis also zack consensus estimate earning stand share year year stryker have earning esp carry zack rank well read more sage unit recall hurt stryker earning mckesson corporation mck free report mckesson major player pharmaceutical medical supply distribution market expect gain gradually stabilize generic brand market company distribution solution segment perform favorably recent time weak pricing trend customer consolidation zack rank company earning have underperform zack consensus estimate average trail quarters mckesson have earning esp mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quote stock have see zack consensus estimate third quarter earning share be revise cent downward last day have also show decline year report figure zack consensus estimate company revenue be peg yet be report quarter compare year figure read more mckesson report earning beat card zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
48,BSX,earning season have kick start last week result participant total market cap have be report so far observed index have make pretty good open respect earning revenue growth latest earning preview oct total earning member go higher revenue member line release quarterly result week be decidedly bullish equity market scenario gradually demonstrate improvement sequentially last quarter look medtech space medical overall growth have be steadily accelerate precede few quarters performance investor be concern medical sector zack sector have see lot struggle past half year thank political power change ongoing policy restructure related battle lack visibility befuddle favorable trend sector be maintain past few quarters third quarter expect earning growth rate be standing revenue growth projection comparison report earning growth rate second quarter be quite impressive revenue growth needless say current crisis medtech industry integral part broader medical sector show sign abate medtech space be earlier hopeful change power white house however be currently fuss total failure republican obamacare repeal replacement consider prevailing uncertainty implementation health policy respite term seem unlikely political turmoil health policy related battle apart majority stock bottom line space be likely be hurt third quarter escalate cost induced consecutive hurricane mexico earthquake give gloomy backdrop investor interested medtech space keenly await earning report key medtech company namely edward lifescience corporation ew free report bard inc oct quantitative model stock solid zack rank strong buy buy hold be combine positive earning esp then chance beating estimate be always high uncover best stock buy sell re report earning esp filter sneak peek stockssimilar sequentially last quarter edward lifescience seem be gain strong transcatheter heart valve therapy thvt segment banking continue therapy adoption geographical region notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last quarter also receipt expand fda approval sapien valve early june top line thvt segment be expect get further boost yet be report quarter read edward lifescience gain thvt earning zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project also zack consensus estimate net sale unite state reflect increase year quarter notably company earning have outpaced zack consensus estimate average trail quarters edward lifescience have earning esp carry zack rank see complete list today zack rank stock here further stock have see zack consensus estimate third quarter earning cent share be revise penny downward last day however have show rally year report figure zack consensus estimate company revenue be peg yet be report quarter improvement year report number regard also anticipate company arch rival transcatheter heart valf space boston scientific corporation bsx free report fare well business third quarter boston scientific be slate report third quarter number oct market open edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote look bard recent performance trend believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst soon be report quarter endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb unite state expect product significantly contribute company top line quarter read cr bard spring surprise earning season notably company earning have outpaced zack consensus estimate average trail quarters bard have earning esp carry zack rank stock have see zack consensus estimate third quarter earning share be revise penny downward last day however have show improvement year report figure zack consensus estimate company revenue be peg yet be report quarter compare year report figure reflect gain regard note bard be slate be acquire becton dickinson company bdx free report fourth quarter acquisition be expect strengthen company footprint home healthcare market unite state bard inc price ep surprise bard inc price ep surprise bard inc quote comparative analysisanalyze revenue driver other fundamental factor edward lifescience bard respective zack consensus estimate conclude edward lifescience be expect perform better bard yet be report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
49,BSX,boston scientific corporation bsx free report be schedule report third quarter result open bell oct last quarter company deliver positive earning surprise trail quarter average beat be peg let see thing be shape prior announcement key catalystswe be optimistic company gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally company gain share number cardiovascular segment de drug eluting stent continue build momentum globally boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote however ahead earning release believe quarter ic business be grossly impact company product recall issue europe notably last february company recall prime product lotus range heart device europe due device malfunction company also delay submission marketing application lotus edge device product line have little hope return european other market fourth quarter lead major setback company fast grow transcatheter aortic valve replacement tavr business ic soon be report quarter believe downbeat ic business earn boost company recent acquisition switzerland base symetis sa full recovery take time accordingly zack consensus estimate third quarter ic revenue be currently peg lower sequentially last quarter report number other factor playamong segment medsurg be expect demonstrate consistent performance lead endoscopy urology woman health be also estimate grow market level drive investment strategy key international geography zack consensus estimate third quarter endoscopy revenue be peg significantly higher year quarter report figure urology woman health current zack consensus estimate remain ahead year report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market remain highly expose currency fluctuation boston scientific expect unfavorable foreign exchange challenge tune revenue bps cent share earning overall boston scientific third quarter adjust earning be expect band cent share revenue here quantitative model predict boston scientific do not have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold increase odd earning beat see complete list today zack rank stock here zack esp boston scientific have earning esp uncover best stock buy sell re report earning esp filter zack rank boston scientific carry zack rank sell fail increase predictive power esp stock considerhere be few medical stock worth consider right combination element beat estimate quarter thermo fisher scientific tmo free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp also carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
50,BSX,boston scientific bsx free report recently launch advanced resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system feature heartlogic heart failure diagnostic notably device be fda approve conditional use magnetic resonance imaging mri environment help physician improve heart failure hf management personalize care device combine company smartcrt technology enduralife battery technology allow physician customize device setting accord individual patient need drain battery have go unnecessary replacement procedure heartlogic diagnostic alarm doctor worsening hf condition combine datum sensor assess heart sound respiration rate volume thoracic impedance heart rate activity crt ds resonate family device be enabled smartcrt technology help physician modify pace lower chamber heart used multisite pace capability multus electrode pace company recently initiate enrolment patient manage hf study further assess heartlogic diagnostic boston scientific recently announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic diagnostic prediction possibility study demonstrated heartlogic diagnostic increase ability classify patient high low risk experience hf event last report second quarter boston scientific cardiac rhythm management crm segment reflect year year increase sale meanwhile company have be consistently focuse product development strengthen position niche accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategically place however company be face tough competition global cardiac monitoring device market establish player abbott free report medtronic plc mdt free report edward lifescience corporation ew free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
51,BSX,boston scientific corporation bsx free report medsurg business group comprise sub segment viz endoscopy urology pelvic health neuromodulation have be record operational sale growth last few quarters expect upside further find reflection first quarter result schedule release apr click here know company overall performance be expect be key be estimate demonstrate steady performance primarily lead endoscopy notably last quarter endoscopy business be fuel biliary hemostasis consistently strong contribution endochoice symetis acquisition endochoice be fully integrate now company be once again expect deliver solid organic operational growth segment first quarter well consequently zack consensus estimate endoscopy revenue indicate rise year quarter boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote urology pelvic health too expect quarter strong growth notably last quarter company single use digital ureteroscope lithovue help drive double digit growth core stone franchise sub segment be also look forward company yet sturdy quarterly performance prostate health significantly urology represent attractive global market potential large unmet patient need horde international expansion opportunity consensus mark endoscopy revenue reflect increase year number neuromodulation company be optimistic robust performance consider rapidly grow niche market believe innovative product launch spinal cord deep brain stimulation franchise likely fuel growth segment be particularly hopeful newly launch wavewriter scs system first only platform approve fda simultaneously provide paresthesia base sub perception therapy patient suffering chronic pain also vercise deep brain stimulation system treat parkinson disease launch last december prove accretive company nuromodulation revenue first quarter zack consensus estimate neuromodulation revenue translate gain year tally zack rank stock considerboston scientific carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report myriad genetic inc mygn free report abiom inc abmd free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here project long term earning growth rate myriad genetic have expect long term earning growth rate stock carry zack rank buy abiom have estimate long term earning growth rate stock have zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
52,BSX,boston scientific corporation bsx free report be schedule report first quarter result open bell apr last quarter company deliver earning line zack consensus estimate however average trail quarter earning surprise be peg let see thing be shape prior announcement key catalystswithin structural heart be look forward boston scientific watchman acurate iris product line expect strongly contribute company top line yet be report quarter earlier company state expect revenue watchman acurate tavr franchise gross approximately be optimistic gradually improve performance interventional cardiology ic lead innovative portfolio robust commercial team globally more specifically company have late successfully gain business strong sale watchman left atrial appendage closure device portfolio complex pci intervention product watchman platform be anticipate experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth apart new launch ic business wolverine cut balloon company next generation rotational atherectomy platform call rotapro be likely strongly contribute top line upcoming quarter be also upbeat company acurate tavr transcatheter aortic valve replacement program have recently complete training european sale clinical team boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote however ahead company earning release first quarter believe ic business be once again deeply impact product recall issue europe notably company have recently announce further delay earlier report timeline commercial return lotus edge aortic valve system europe well unite state follow product voluntary recall last february other factor playamong segment medsurg be estimate demonstrate steady performance lead endoscopy urology woman health be also project grow market level drive investment strategy key international geography however company be expect face business too yet be report quarter headwind come form year year difficult pacer comparison more competition drug eluting stent space new entrant overall zack consensus estimate first quarter endoscopy revenue be peg prior year quarter report count urology woman health consensus mark remain ahead year earlier quarter report tally flip side severe currency headwind boston scientific have be face late remain concern fact company record sale international market get highly expose currency fluctuation apart immaterial be report quarter ongoing tension unite state well china regard imposition tariff import have raise concern major medtech player adverse move affect top line number future here quantitative model predictsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp boston scientific have zack rank increase predictive power esp earning esp make surprise prediction difficult together combination do not suggest company be likely beat earning quarter caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider right combination element beat estimate time myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp be zack rank player today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
53,BSX,medtronic plc mdt free report recently initiate post market forward pro clinical study measure performance corevalve evolut pro transcatheter aortic valve implantation tavi system regular clinical treatment study evaluate long term performance next generation self expand tavi system patient severe symptomatic aortic stenosis be intermediate high extreme risk open heart surgery notably system have recently be approve commercial use europe unite state management multus center study enroll patient site europe moreover study involve measure safety standard corevalve evolut pro valf analyze cause mortality stroke rate day clinical performance cover valve hemodynamic paravalvular regurgitation moreover company patient be continue be follow evaluate year encouragingly note march corevalve evolut pro system have receive fda approval use symptomatic patient be high extreme risk open heart surgery moreover self expand tavi system have be grant regulatory approval europe well thus believe clinical study datum display efficiency product help company gain traction coronary structural heart csh space interestingly medtronic csh revenue be constant exchange rate back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform unite state continue demand corevalve evolut mm valve unite state well europe notably report medgadget global heart valve repair replacement market be expect grow cagr believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr medtronic be base highly fragmented heart valve repair replacement market however market be dominate well establish player abbott free report boston scientific corporation bsx free report edward lifescience corporation ew free report other boston scientific lotus valve platform edward lifescience sapien xt sapien offering be worth mention here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
54,BSX,sep issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry several issue stock have improve compare broader industry gain period adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotehowever give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned strengthen core business invest more global market recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity zack rank key picksboston scientific carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
55,BSX,abbott laboratory free report have make encourage move respect medical device business company recently announce fda approval full maglev heartmate left ventricular assist device lvad build sophisticated full maglev fully magnetically levitated flow technology heartmate system provide advanced short term hemodynamic support advanced heart failure patient full maglev technology enable heartmate system lower trauma blood pass pump optimize blood flow interestingly heartmate be upgrade version exist heartmate ii system be used longer duration much await fda approval be award abbott post successful result momentum clinical study also encouragingly note heartmate receive ce mark management person unite state suffer heart failure roughly new patient be diagnosed condition year support datum statista report heart failure market state market be project value witness cagr moreover see encourage growth user penetration rate share ailing person thus consider datum base believe latest fda nod accelerate top line growth report culrav org global lvad market be project value witness cagr moreover transperency market research north american market ventricular assist device be expect see cagr period thus consider market potential abbott latest development help gain traction lvad space interestingly abbott medical device operate segment total revenue stand highest revenue gross business second quarter moreover company cardiovascular neuromodulation sub segment be highest contributor make total medical device revenue sale unite state alone thus company latest development help boost performance segment believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth heart failure market however market be dominate many well establish player medtronic plc mdt free report boston scientiific corporation bsx free report be most prominent one moreover abbott have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank key pickabbott carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
56,BSX,second quarter earning season gain momentum broader picture longer look bright be expect be putt together member release result jul constitute index total membership note earning growth pace be less last quarter however be more less line trail quarter average earning growth exceed trail quarter average latest second quarter scorecard total earning increase year year higher revenue earning beat ratio remain revenue beat ratio be more information please consult zack earning analysis store medical space investor be concern healthcare space sector have be see lot struggle past half year thank political power change ongoing policy restructure related battle yesterday be finally president donald trump republican healthcare bill pass more barrier very narrow margin investor be however not much optimistic development vox article today effort repeal replace obamacare president donald trump continue make bold promise bill do promise available analysis suggest bill not keep be still chance senate amend latest bill extent still remain unclear accordingly uncertainty medical space be towering high investor be currently adopt see policy space let sneak peek performance major medical product company broader medical space expect jul align technology inc algn free report be upbeat align technology execution strategic initiative international expansion ensure invisalign treatment grow base patient context company strengthen foothold internationally acquire invisalign distributor highly lucrative europe middle east africa emea region well brazil february be likely drive company result soon be report quarter align be expect beat expectation report second quarter result market open have right combination key ingredient stock currently carry zack rank strong buy have earning esp note positive zack esp serve lead indicator likely positive earning surprise bullish zack rank increase predictive power esp uncover best stock buy sell re report earning esp filter read more align technology earning beat card align technology inc price ep surprise align technology inc price ep surprise align technology inc quote boston scientific corporation bsx free report believe medical device major second quarter performance be grossly impact company product recall issue europe other hand company downbeat interventional cardiology business get sort boost company acquisition switzerland base symetis sa boston scientific be schedule report second quarter result market close company currently carry zack rank sell have earning esp hence be unable conclude boston scientific be likely beat earning quarter note sell rate stock never be consider go earning announcement read more boston scientific earning await stock boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quote cerner corporation cern free report believe cerner strong sale performance well solid portfolio strategic initiative have position well stellar growth cerner announce have be choose department veteran affair develop electronic health record ehr system department veteran affair use same system company be develop department defense begin operation first site february system facilitate exchange datum military care facility civilian health provider current former service member receive care lead healthcare information technology hcit company be schedule report second quarter earning market close company currently carry zack rank earning esp hence be expect beat expectation quarter see complete list today zack rank stock here read more cerner deliver beat earning season cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotestryker corporation syk free report second quarter renown medical device maker expect adjust earning share range notably indicate rise year year basis believe grow adoption mako robot drive sale orthopedic reconstructive surgery market additionally stryker be well poise acquisition sage physio control past company also expect beat expectation report second quarter result close bell be stock currently carry zack rank hold earning esp read more stryker deliver beat earning season stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quote mckesson corporation mck free report major player pharmaceutical medical supply distribution market expect gain gradually stabilize generic brand market company distribution solution segment perform favorably fiscal weak pricing trend customer consolidation be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp need have positive esp be confident earning beat read more mckesson earning stock likely beat estimate mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
57,BSX,boston scientific corporation bsx free report recently announce acquisition securus medical group inc privately hold developer thermal monitoring system continuous measurement esophageal temperature buyout be line company strategy gain traction global ep market be poise reach value datum market market securus medical group integrate catheter base probe imaging system produce real time image temperature esophagus help perform cardiac ablation procedure avoid thermal injury notably infrared esophageal temperature monitoring system have receive clearance fda boston scientific plan introduce thermal monitoring system unite state first half further company integrate thermal monitoring system rhythmia hdx mapping system improve level comprehensive cardiac imaging ablation procedure financial term dealboston scientific have exist investment securus medical group pay net upfront payment approximately cash remain stake milestone fee nearly however transaction be not expect be accretive company adjust earning share glimpse ep businessboston scientific ep business develop less invasive medical technology diagnose treat disorder heart rate rhythm fourth quarter revenue division improve year year cer upside be drive higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently launch unite state well japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system additionally focus add tool expand reach utility rhythmia hdx different procedure regard boston scientific expect full fledge directsense technology europe unite state follow successful initial launch europe moreover expand ep business boston scientific acquire apama medical inc october company intend integrate rhythmia hdx mapping system apama rf balloon system improve visualization heart ablation process market potentialboston scientific strategy boost ep business seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect reach value cagr believe unhealthy lifestyle rise age population continue result high incidence cardiovascular disease be support datum provide gbi research report global cardiovascular disease market be project witness cagr space market be expect witness highest momentum cagr thus addition thermal monitoring system help boston scientific cash abundant opportunity global cardiac monitoring cardiac rhythm management market share price scientific have be gain investor confidence consistently positive result past month share company have outperformed broader industry stock have rally versus industry decline zack rank key picksboston scientific carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report align technology inc algn free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate align technology have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
58,BSX,lead way grow market urology boston scientific corporation bsx free report have recently enter agreement buy minnesota base nxthera deal value privately hold nxthera be developer marketer rezum system unite state europe transaction be expect complete second quarter subject customary close condition financial term transaction consist upfront payment cash additional potential commercial milestone payment next year notably company have exist minority investment nxthera expect result net upfront payment approximately close milestone fee nearly nxthera rezum bph strategic deal bsx patient symptom arise benign prostatic hyperplasia bph rezum system nxthera come minimally invasive therapy option bph cancerous prostate gland enlargement be quite common age male create attractive market disease affect man worldwide more symptomatic man alone unite state be undergo treatment condition medication procedural approach notably bph cause symptom affect patient qualify life such pain frequent need urinate many positive rezum system nxthera be impressed hassle free procedure be perform physician clinic general anesthesia thereby reduce cost bph therapy core moreover treatment apply water vapor remove excess prostate tissue alleviate obstruction urine flow further help mitigate bph related symptom also prevent unwanted side effect come intake maintenance medication control bph boston scientific mentioned favorable clinical study related rezum system management state study publish march issue journal urology demonstrated year period patient treat rezum system have clinical progression rate be time lower report rate patient treat daily long term medication additional clinical datum randomize controlled trial demonstrated patient treat rezum system have reduction symptom month post treatment maintain percent reduction bph symptom year post treatment project synergy dealpost deal closure buyout nxthera be expect remain immaterial boston scientific adjust earning share ep be only accretive afterwards consolidation be likely be dilutive less beneficial report basis due amortization transaction integration cost reckon boston scientific urology pelvic health arm be highest operate margin business company acquisition am urology portfolio have burgeon urology business size almost double value significantly urology represent attractive global market potential large unmet patient need considerable international expansion opportunity believe nxthera buyout post completion enable company capitalize opportunity share price performance boston scientific have be gain investor confidence consistently positive result last month share company have outperformed broader industry stock have rally compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
59,BSX,era big datum portfolio be tune evolve digital trend make prudent investment choice prove be daunting task millennial have start recognize increase need emerge automation trend subsequently robotic iot printing be become part daily life latest buzzword be artificial intelligence ai siri google have make life easier latest version global position system help track almost anything everything intelligent route map also not be pro social network site facebook twitter snapchat be see primitive accord investment giant jim cramer ai big datum soon let company bat interestingly benefit same not remain restrict particular industry be feel business segment investment arena ai help medtech gain tractionnon healthcare bigwig apple aapl free report google amazon amzn free report ibm microsoft digital affluence be already eyee healthcare device market late courtesy solid prospect thing be note here health treatment cost have sky-rocket past few year surprisingly medical device pharmaceutical account only small portion healthcare expense josh makower md general partner venture capital firm new enterprise associate greater part healthcare cost go pay salary healthcare employee ai help curtail high labor cost go deloitte datum global health care spending be project increase annual rate significant escalation just report rise labor cost be act major spending growth driver also growth age population necessity ai have increase leap bound census bureau report be significant rise age population unite state population age older be project be almost double estimate population datum also show median age be increase most area country be global scenario well notably industry be bearing brunt explode population present world health organization latest available datum show more member state worldwide report have less physician population density physician patient unite state be strategic application ai sphere healthcare provide impetus productivity evidently company adopt ai technology have already witness reduction healthcare cost have also experience improve patient outcome more medtech stock go ai waymedtronic mdt free report be undoubtedly first medtech manufacturer forge ahead initiative bring ai technique manufacturing process back company partner ibm watson utilize latter machine learn algorithms incorporate ai diabetes app minime jointly launch first artificial pancreas system metronic have utilize sugar iq cognitive compute capability ibm watson detect important pattern trend diabetes ehr technology developer cerner cern free report be also adopt ai technique rapidly lately company have be headline courtesy effort digitize electronic health record system regard company recently enter collaboration salesforce renown player field customer relationship management other centrus health clinically integrate physician lead network latest development company be plan advance flagship big datum platform healtheintent intuitive surgical isrg free report design manufacture market da vinci surgical system advanced robot assist surgical platform ai platform enable minimally invasive surgery help negate trauma associate open surgery company plan expand usage da vinci general thoracic surgery colorectal surgery hernia repair late boston scientific bsx free report have also be putt effort incorporate ai technique neuromodulation cardiac rhythm management cardiology peripheral intervention oncology endoscopy urology pelvic health conclusiona long debate be structure intelligent machine intensive technology make human capability outmoded gradually different story several adversity ai undoubtedly have emanate change behavioral pattern consumer medical device space other sector once again go jim cramer say love behavior change investing be incredibly lucrative have behavior change theme use selloff pick stock base change thus go say market hold ample promise proper execution ai definitely prove be trump card space zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
60,BSX,fourth quarter earning season be gain momentum participant have already release financial number jan latest earning preview report cycle be encourage start average proportion company edge past top bottom line expectation total earning member have improve increase revenue result roughly member slate be announce week zack datum estimate period be gradually trend upward board zack sector medical bracket be expect witness earning rise fourth quarter revenue growth projection store medical device industry medical device space broader medical sector somewhat display mixed bag sort part tax overhaul corporate tax rate have be slash previous thus lend huge relief medtech mammoth however ahead industry fourth quarter earning release section analyst expect new tax law negatively impact industry due possible cut overall medicare spending certain criterium be not fulfilled specific date congressional budget office apprehend absence alternative meet fiscal deficit huge tax reduction automatic cut back worth include medicare cut mandatory budget spending be trigger tax reform related concern news congress delay medical device tax year come huge boost industry player investor tax be earlier delay congress couple year deferral once again largely propel activity space let take sneak peek performance major medical device company wait report earning feb boston scientific corporation bsx free report be optimistic company gradually improve performance interventional cardiology lead innovative portfolio robust commercial team globally more specifically watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth company have positive earning esp zack rank hold favorable zack esp indicate likely positive surprise bullish zack rank strong buy buy increase predictive power esp conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision read more watchman boost boston scientific earning boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotebaxter international inc bax free report fourth quarter baxter international be anticipate gain strong hospital product drive solid sale fluid system business well robust demand injectable pharmaceutical hospital product segment expect fluid system maintain momentum evident zack consensus estimate be report quarter reflect improvement year period banking solid prospect quantitative model also show beat company give combination zack rank earning esp uncover best stock buy sell re report earning esp filter read more baxter beat earning hospital product baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotemckesson corporation mck free report major player pharmaceutical medical supply distribution market expect witness solid performance canadian business third quarter fiscal also mckesson specialty health unit be likely drive company top line same time frame unit be likely benefit close intrafusion acquisition recent bdi pharma buyout be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp however need have positive esp be confident earning surprise see complete list today zack rank stock here read more mckesson report earning beat card mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quoteedward lifescience corporation ew free report lead cardiovascular product maker be expect grow robust transcatheter heart valve therapy segment fourth quarter back continue therapy adoption geography notable strength unite state company be likely retain bullish run period be report edward lifescience be zack rank player have earning esp positive zack esp denote likely earning surprise favorable zack rank company raise predictive power esp read more edward lifescience thvt likely drive earning edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quoteidexx laboratory inc idxx free report repeating precede quarter success idexx be estimate gain strong global footprint companion animal group diagnostic recur revenue fourth quarter be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic company be rank player have earning esp therefore be unable conclude idexx be likely beat earning quarter however idexx trail month average beat be read more idexx post beat earning cag strength idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
61,BSX,boston scientific corporation bsx free report post adjust earning share ep consider certain time adjustment other amortization expense cent second quarter year quarter consider amortize expense adjustment quarter adjust ep come cent year adjust number figure remain penny ahead zack consensus estimate fall company adjust ep guidance range cent adjustment company report earning cent share comparison loss cent share year period boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoterevenue detailrevenue second quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate organic revenue growth second quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically second quarter company achieve operational growth organically europe asia middle east africa region emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively second quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm increase defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin expand basis point bps year year fall cost product sell adjust operate margin also expand bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit second quarter cash cash equivalent end sequential last quarter end second quarter company have total long term debt marginal increase end first quarter guidanceboston scientific have provide update full year guidance company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly increase earlier range zack consensus estimate be guide range company also provide third quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takeeven challenge economic condition competitive environment severe currency headwind boston scientific post better expect second quarter earning miss zack consensus estimate revenue ahead mark foreign exchange headwind continue challenge be concern company recent recall prime product lotus range heart device also unimpressive defibrillator performance company core crm segment continue remain drag overall growth nevertheless boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography second quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition switzerland base symetis sa bid fortify structural heart business europe apart company receive fda approval resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system also receive ce mark vercise gevia deep brain stimulation dbs system first mr conditional directional dbs system treatment movement disorder symptom patient parkinson disease dystonia essential tremor zack rank other key pickscurrently boston scientific carry zack rank sell other better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
62,BSX,base boston scientific corporation bsx free report be lead global manufacturer medical device be used wide range interventional medical specialty boston scientific technology address wide range health condition business unit be organized global report segment rhythm management cardiovascular medsurg currently boston scientific have zack rank sell change follow second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning zack consensus estimate remain steady cent share last day boston scientific adjust earning cent share surpass zack consensus estimate boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quoterevenue post revenue comfortably beating zack consensus estimate revenue key stat second quarter boston scientific cardiovascular segment revenue increase rhythm management segment revenue grow totale other hand revenue medsurg segment improve major factor boston scientific have post impressive second quarter result deliver revenue growth segment moreover report quarter company have close acquisition symetis privately hold swiss structural heart company also company have win fda nod resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system company have raise full year outlook revenue adjust earning stock price follow earning release share price do not show movement pre market trading session check back later full boston scientific earning report later more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
63,BSX,boston scientific corporation bsx free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session stock picked sharply flat trend past month time frame move come company announce preliminary unaudited sale roughly fourth quarter end dec represent roughly growth report basis company have see mixed track record come estimate revision increase decrease past few month zack consensus estimate current quarter remain unchanged recent price action be encourage so make sure keep close watch firm future boston scientific currently have zack rank sell earning esp be positive boston scientific corporation price boston scientific corporation price boston scientific corporation quoteinvestor interested medical product industry consider bio rad laboratory inc bio free report have zack rank strong buy see complete list today zack rank stock here be bsx go predict see other think downlooking stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
64,BSX,boston scientific bsx free report be hit headline successive new development latest feat be company spectra wavewriter spinal cord stimulator system scs get fda nod boston scientific be only fda approve scs system provide paresthesia base sub perception therapy notably scs technology send low electrical pulse varied frequency pulse width amplitude spinal cord interrupt pain signal paresthesia base therapy provide pain relief light tingle sensation sub perception therapy work company claim latest spectra wavewriter system effectively enable physician patient combine therapeutic option customize therapy well capture real time feedback treat chronic debilitating pain address individual distinctive pain relief need spectra wavewriter system disposal boston scientific view patient easily combine paresthesia base sub perception therapy target specific area pain else pick particular therapy require best manage multiple area pain additionally patient provide real time feedback used system remote control datum provide transparency market research global pain management therapeutic market be expect witness cagr accordingly market be anticipate rise promising datum make confident grow acceptance boston scientific spectra wavewriter spinal cord stimulator system company note more american suffer chronic pain thus make prime cause disability adult unite state company commitment invest research well expand treatment option chronic pain identify new opioid solution scs appear be perfectly strategic share price movement boston scientific have be outperform broader industry past day stock have rally compare broader industry gain key picksboston scientific carry zack rank sell better rank stock broader medical space be bio rad laboratory bio free report centene corporation cnc free report molina healthcare inc moh free report sporting zack rank strong buy see complete list today zack rank stock here bio rad have whopping expect growth rate first quarter stock have jump surpass broader industry year centene have expect long term growth rate stock performance bourse have be solid year time high return molina healthcare have solid project growth rate last month stock have surge higher broader industry rally wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
65,BSX,angiodynamic inc ango free report report adjust earning cent share second quarter fiscal earning miss zack consensus estimate penny decline year year basis meanwhile net sale fall almost year year miss zack consensus estimate net sale be due decline venous core piccs business international net sale be year year basis owing robust sale oncology surgery business decline venus insufficiency core business majority company vascular access bioflo product be primary reason downside overall revenue significant impact currency have be observed report quarter angiodynamic inc price consensus ep surprise angiodynamic inc price consensus ep surprise angiodynamic inc quotesegment vascular pv business sale segment totale report quarter year quarter growth fluid thrombus management product line be offset decline venous insufficiency angiographic catheter business well persistent wind company supply agreement boston scientific corp bsx free report notably angiodynamic be lead player thrombolytic catheter space catheter direct thrombolysis company boast highly unique catheter uni fuse speedlyser pulse spray thrombus portfolio vascular access va business sale segment be year year basis segment witness solid sale bioflo related product however be offset decline remain product line segment oncology surgery business angiodynamic witness sale second quarter increase year year basis upside be primarily drive additional sale recently launch solero microwave tissue ablation system margin detailsa percentage revenue adjust gross margin contract basis point bps second quarter fiscal year quarter decline gross margin be primarily inventory related volta company radio frequency ablation product be previously sell japan adjust ebitda second quarter fiscal be compare second quarter fiscal financial have strong cash flow balance second quarter management company generate operate cash flow free cash flow additionally angiodynamic end quarter cash cash equivalent debt fy view lack reduce guidance fiscal fiscal company expect net sale range compare previous range free cash flow be expect range however company have reaffirm previously announce adjust earning share guidance range cent exclude impact recently legislate tax reform act report dismal second quarter fiscal adjust earning revenue miss zack consensus estimate company also reiterate guidance fiscal angiodynamicis ride market solid response solero especially microwave ablation space management angiodynamic consistent focus financial discipline build high quality capital structure boost investment innovative product portfolio pursue strategic acquisition flipside drop core angiographic catheter business have affected peripheral vascular business segment company also have high outstanding debt level higher debt impose certain operate financial restriction limit execution company core business strategy price have be perform industry last month stock have lose industry gain zack rank key hold zack rank hold few better rank stock broader medical space be abiom inc abmd free report integer holding corp itgr free report carry zack rank buy see complete list today zack rank stock here abiom have impressive long term growth rate last month stock have rally compare industry gain integer holding expect grow next quarter last year company share have gain surpass industry rally zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
66,BSX,jan issue update research report lead medical device company boston scientific corporation bsx free report stock carry zack rank hold past month boston scientific have be trading broader industry several issue stock have decline compare broader industry gain period positive note gradually improve foreign exchange scenario have also start contribute company overall top line performance raise guidance be more impressive indicative overall bullish trend continue rest company report final quarter earning performance boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography third quarter be also encourage company gain number approval product domestic well overseas market recent development worth mention be company recent acquisition apama medical developer single shot apama radiofrequency balloon catheter system treatment atrial fibrillation apart company receive fda approval mri labele announce launch resonate family implantable cardioverter defibrillator cardiac therapy defibrillator crt system combine heartlogic heart failure diagnostic enduralife battery technology smartcrt technology however be concern company recall prime product lotus range heart device recently company announce delay earlier report timeline commercial return lotus edge aortic valve system europe unite state follow product voluntary recall take place last february upcoming fourth quarter earning conference call schedule feb company now expect provide further update status lotus edge valve also dull defibrillator sale core cardiac rhythm management continue be drag overall growth additionally wo challenge economy well competitive landscape persistently burden stock key pickssome better rank stock broader medical space be akari therapeutic plc aktx free report protagonist therapeutic inc ptgx free report xoma corp xoma free report sporting zack rank strong buy see complete list today zack rank stock here akari have project growth rate next quarter earning surprise deliver company have be positive last quarters average beat protagonist have expect earning growth rate stock have soar impressive last month xoma be expect score impressive earning growth rate stock have sky-rocket whopping last month loss incur broader industry investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
67,BSX,boston scientific corporation bsx free report have be dominate headline late courtesy fda approval vercise deep brain stimulation dbs system device be used treat symptom parkinson disease pd first commercial implant vercise system be do university minnesota medical center minneapoli mn study support approval come back encourage datum intrepid study first multus center prospective double blind randomize sham controlled study dbs pd unite state study confirm effectiveness safety system moreover system record positive safety datum european multus center prospective single arm vantage study development dbs portfolioboston scientific witness improvement neuromodulation business last report quarter several product launch include vercise gevia mri dbs europe cartesia lead june provide first directional rechargeable magnetic resonance mr conditional system company also introduce neural navigator programming software allow physician visualize stimulation field configure dbs program patient boston scientific be also currently support research use dbs stroke recovery treat alzheimer disease market potentialper transparency market research report global dbs market be project reach value cagr prospect market be primarily base increase number person suffering neurological disease age group company more person unite state globally be suffering pd thus latest fda approval help boston scientific cash bountiful opportunity dbs market share price movementover past month boston scientific have be underperform broader industry stock have decline contrast broader industry gain latest fda approval be expect help stock bounce back zack rank key picksboston scientific currently carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year time more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
68,BSX,fate lotus valve issue seem be limbo more time boston scientific bsx free report recently company announce delay earlier report timeline commercial return lotus edge aortic valve system europe unite state follow product voluntary recall take place back february follow sudden announcement share price company drop last day reach close session nov editor amanda pedersen newsletter publish mddionline com investor be overly worry due sudden change plan foreshadow lotus setback notably february recall product base certain device malfunction boston scientific announce expect time reintroduction lotus edge delivery system europe first quarter company also expect file final pre market approval pma module food drug administration january however latest press release fourth quarter earning conference call feb company now expect provide further update status lotus edge valve delay have be justified boston scientific cite continuous focus manufacturing regulatory milestone support long term success lotus platform company state be currently work implement necessary modification device pass internal quality standard company have not specifically mentioned exact reason postpone lotus valve relaunch however fear uncertain fate company fast grow transcatheter aortic valve replacement tavr business interventional cardiology lotus valve line be prime product meanwhile company observed delay be not expect bring financial impact fourth quarter guidance boston scientific have be trading broader industry past month stock have lose compare broader industry rise period zack rank key pick boston scientific carry zack rank hold better rank stock broader medical sector be petm express inc pet free report myriad genetic inc mygn free report luminex corp lmnx free report sporting zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year myriad genetic have long term expect earning growth rate stock have soar year luminexha long term expect earning growth rate stock have gain last year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
69,BSX,few month line republican complete full year power unfortunately political power change healthcare community hasn have many opportunity rejoice survey report gallup analytic last month reveal adult cite healthcare second major problem face country new presidential administration fact debate repeal affordable care act aca obamacare have be rage now report peaked reach congress august consider prevailing uncertainty implementation health policy respite term seem unlikely medtech unite state blur pictureneedless say current crisis medtech industry integral part broader healthcare space show sign abate few month back company space be hopeful promise cancellation medtech tax obamacare new government unquestionably latest political development have land medtech space uncertain territory investor be mull retain exist medtech stock forego holding favor company other industry boost financial resource say spite future hold believe investor stick medtech space have show sign prosperity recent time globally yes read right even consider dull performance medical device market still hold lead position almost third world market share rise regulatory legislative uncertainty global growth have be quite encourage industry grow pace last see financial crisis emerge market hold immense uncertainty unite state worsening economic condition europe automatically shift focus emerge geography china india latin america other emerge economy be see rise uptake medical device largely due grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage make market happy hunting ground global medical device player add rise healthcare spending improve healthcare infrastructure growth continue go recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india medtech market fifth largest world be currently demonstrate annual growth continue india give good competition japan germany other emerge geography latin america even face general economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare period accord world bank datum guatemala increase spending brazil chile colombia uruguay paraguay ecuador lower domestic production latin america have make open market exporter investment emerge market player look sensiblein such scenario believe be wise investor be keen medtech stock keep eye company have turn emerge market happy hunting ground expertise network wonder stock cash enormous growth potential emerge geography have perfectly shield political turmoil unite state let look few medtech player significant emerge market presence give huge potential region long back johnson johnson jnj free report have set manufacturing center brazil china india company medical device segment emerge market be grow time faster develop market have be do business china nearly year be expand further here back synthe acquisition johnson johnson price consensus johnson johnson price consensus chart johnson johnson quote abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina abbott laboratory price consensus abbott laboratory price consensus chart abbott laboratory quote medtronic mdt free report last report first quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic remain confident long term outlook emerge market company be focuse develop new public private partnership well execute channel optimization strategy medtronic plc price consensus medtronic plc price consensus chart medtronic plc quote boston scientific bsx free report emerge market business register organic growth second quarter significant increase growth business china be once again remarkable year year company be currently look forward much better performance ahead china banking recent approval synergy china boston scientific corporation price consensus boston scientific corporation price consensus chart boston scientific corporation quote thermo fisher tmo free report too be leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus chart thermo fisher scientific inc quote wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
70,BSX,oct issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry stock have improve compare broader industry gain period recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic well overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotewhile adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock however give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned reinforce core business invest more global market zack rank key picksboston scientific carry zack rank hold few better rank stock medical sector be orthofix international ofix free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report orthofix international sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
71,BSX,boston scientific corporation bsx free report recently announce plan acquire campbell base privately hold company apama medical inc total value be line company strategy gain traction market be poise reach value more datum article factory deal be slate close fourth quarter subject customary close condition acquisition agreement subject attainment certain clinical regulatory target boston scientific be schedule pay maximum contingent payment cash immediate basis however company do not expect buyout prove accretive adjust earning even apama medical be involved research development apama radiofrequency rf balloon catheter system treatment atrial fibrillation af management af be heart rhythm disorder have affected roughly globally deal boston scientific aim expand suite arrhythmia solution fall sub segment company company also intend integrate rhythmia hdx mapping system apama rf balloon system order enhance visualization heart ablation process apama rf balloon be expect receive ce mark approval late af ficient study result present af symposium annual meeting january have be favorable interestingly boston scientific revenue improve last report quarter higher uptake new rhythmia hdx platform management continue roll hdx platform europe recently initiate same unite state japan overall company continue expand toolkit support rhythmia hdx provide ablation technology match excellence mapping system add tool expand reach utility rhythmia hdx different procedure type context company plan launch intellanav mifi open irrigate therapeutic catheter europe unite state third quarter moreover boston scientific strategy gain traction sub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr share price scientific have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain compare broader industry gain zack rank key picksboston scientific currently carry zack rank hold few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex corporation sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex corporation have long term expect earning growth rate stock gain last month idexx laboratory have long term expect earning growth rate stock gain last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
72,BSX,abbott free report ellipse implantable cardioverter defibrillator icd recently gain fda approval magnetic resonance mr conditional labele solidify company footprint rhythm management space post approval patient implanted ellipse device durata optisure lead be able undergo mri scan moreover ellipse now be available patient suffering severely high heart rhythm need icd mri scan thus believe latest regulatory approval expand company customer base drive top line moreover ellipse be embed feature know abbott tailoredtherapy be capable directly securely wirelessly forwarding therapy related datum patient physician merlin net patient care network continue effort expand mr conditional labele enabled device company receive fda approval mr conditional labele assurity mri pacemaker tendril mri pace lead also company have receive certain prior mr conditional labele approval europe meanwhile abbott have apply fda approval mri conditional labele quadra assura cardiac therapy defibrillator crt product quartet family left ventricular lead interestingly company witness softness rhythm management segment majorly due tough competition mri conditional category product market be dominate well establish player medtronic plc mdt free report boston scientific corporation bsx free report edward lifescience corporation ew free report other abbott strategy gain traction rhythm management sub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
73,BSX,boston scientific bsx free report announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic heart failure diagnostic predict impending heart failure hf decompensation study demonstrated heartlogic diagnostic iincrease ability classify patient high low risk experience future hf event presently physician recommend blood test diagnose hf determine disease severity however method be less reliable assessment lose relevance patient condition change multisense trial datum show heartlogic diagnostic expand ability baseline blood test identify patient high risk hf event notably heartlogic diagnostic be already ce marked fda approve be available commercially later year rhythm management segment last report second quarter rhythm management be second largest contributor boston scientific top line include cardiac rhythm management crm crm reflect year year increase sale report quarter accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategic fit past year boston scientific have be trading broader industry stock have rise period gain broader industry estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksboston scientificcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
74,BSX,boston scientific corporation bsx free report be schedule report second quarter result open bell jul last quarter company earning miss zack consensus estimate however post average beat trail quarters let see thing be shape prior announcement factor playahead boston scientific earning release believe quarter performance be grossly impact company product recall issue europe notably earlier year news surface boston scientific be recall prime product lotus range heart device europe device malfunction abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory company also delay submission marketing application lotus edge device lotus remediation work be currently track product line have little hope return european other market fourth quarter lead major setback company fast grow transcatheter aortic valve replacement tavr business interventional cardiology have high chance severely weigh company second quarter revenue result apart severe currency headwind boston scientific have be face lately remain concern note company record sale international market remain highly expose currency fluctuation boston scientific expect unfavorable foreign exchange headwind tune revenue bps cent share earning adjust gross margin full year assume negative foreign exchange impact bps positive angle company downbeat interventional cardiology business get sort boost company acquisition switzerland base symetis sa privately hold structural heart company completion acquisition back boston scientific have already begin selling valve system europe other geography outside company believe symetis acurate group valve product strongly complement aortic valve platform integrate technology not only diversify boston scientific structural heart portfolio also provide cardiac surgeon multiple tavi offering vary patient pathology anatomy expect see contribution development second quarter revenue subsegment namely medsurg be expect demonstrate consistent performance lead endoscopy urology woman health be also estimate grow market level drive investment strategy key international geography state earlier company overall second quarter adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be earning whispersour proven model do not conclusively show boston scientific be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp boston scientific earning esp be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank boston scientific currently have zack rank sell please note caution sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be better rank company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex inc tfx free report have earning esp zack rank more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
